Method for determining aav genome
By treating samples with proteinase K in the presence of detergent, the problem of underestimated AAV vector genome copy number was solved, achieving more accurate viral genome quantification and meeting relevant standards.
Patent Information
- Application Number
- CN202380032839.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-13
- Filing Date
- 2023-04-11
- Publication Date
- 2024-11-15
AI Technical Summary
Existing techniques for determining the copy number of adeno-associated virus (AAV) vector genome have the problem of underestimating the viral genome copy number in the sample, especially when the sample contains non-viral capsid DNA. Conventional processing methods can lead to aggregate formation, which affects the PCR amplification effect.
Samples were treated by incubating with proteinase K in the presence of detergent to avoid the formation of aggregates of protein fragments and viral genomic DNA, ensuring that the viral genome could be effectively amplified in digital droplet polymerase chain reaction (ddPCR).
This improved the accuracy and recovery rate of AAV genome copy number determination, met the acceptance criteria of the EMA and FDA, and ensured the reliable quantification of viral genome copy number.
Smart Images

Figure BDA0005072956920000251 
Figure BDA0005072956920000252 
Figure BDA0005072956920000261
Abstract
Description
[0001] The invention belongs to the field of gene therapy. In more detail, herein is reported a method for determining viral genome copy number in process and purified samples using ddPCR, wherein the samples are incubated with proteinase K in the presence of a detergent prior to PCR. Background Art
[0002] Adeno-associated virus (AAV) particles are commonly used as gene transfer vehicles for research and clinical approaches due to their favorable safety profile, high therapeutic efficacy, and the possibility of target-specific engineering. For recombinant production, accurate and robust analytical methods for viral vector characterization are required. Typically, vector genome titration is performed by droplet digital PCR (ddPCR), a method for absolute quantification of nucleic acids.
[0003] In the literature, several pretreatment methods for AAV vector genome titration have been reported for both real-time and droplet digital PCR. Before absolute quantification of the target sequence within the capsid, free transient plasmids and other unpackaged nucleic acids (such as host cell DNA) need to be degraded with nucleases such as DNase I (Zolotukhin, S. et al. 1999; Furuta-Hanawa, B. et al. 2019; Fripont, S. et al. 2019; Dobnik, D. et al. 2019; Sanmiguel J. et al. 2019). In addition, the capsid needs to be degraded to obtain better accessibility to the vector genome. Heat inactivation of AAV particles and the resulting denaturation of their capsid proteins are sufficient to achieve this purpose (Wang, Y., et al. 2019). However, in most publications, additional protein digestion with proteinase K is described (Zolotukhin, S. et al. 1999; Fripont, S. et al. 2019; Dobnik, D. et al. 2019; Sanmiguel J. et al. 2019). In addition, there are various suggestions for dilution buffers for subsequent dilution series of treated samples: in addition to nuclease-free water (Zolotukhin, S. et al. 1999), TE buffer (Furuta-Hanawa, B. et al. 2019; Wang, Y. et al. 2019) or PCR buffer (Sanmiguel J. et al. 2019), additives such as the antisurfactant Pluronic F-68 (Furuta-Hanawa, B. et al. 2019; Sanmiguel J. et al. 2019) and sheared salmon sperm (sss) DNA (Lock, M. et al. 2014; Sanmiguel J. et al. 2019) are also described in the literature.
[0004] Suoranta, T. et al. (Hum. Gen. Ther. 32 (2020) 1270-1279) compared the extraction of AAV1, AAV2, AAV5, AAV6, AAV8, and AAV9 genomes after iodixanol gradient ultracentrifugation in phosphate-buffered saline solution by heat denaturation, proteinase K treatment, and kit extraction using qPCR and ddPCR. Kit extraction (which contains proteinase K treatment in the presence of additional carrier RNA in a denaturing buffer before spin column purification) significantly increased the titers obtained for all serotypes in both qPCR and ddPCR. Importantly, Suoranta et al. found that no study has yet presented conclusive data on the availability of genomes in ddPCR.
[0005] CN 109957561 discloses a method for extracting nucleic acid from a sample, wherein the method comprises the following steps: adding a lysis solution to the sample to be extracted to release nucleic acid molecules; further adding a sodium lauroyl sarcosine salt solution; further adding a mixed solution containing sodium iodide, glycogen and isopropanol to form a precipitate containing nucleic acid, and recovering the precipitate by centrifuging the sample.
[0006] US 8,652,821 discloses a reagent mixture for purifying RNA-free DNA, which comprises a protease, an RNase and a detergent.
[0007] US 11,028,372 discloses a scalable purification method for AAV particles of serotype rh.10.
[0008] WO 03 / 104413 discloses a dot blot analysis of pseudotyped recombinant AAV virions, not further specified, comprising proteinase K incubation followed by phenol extraction and ethanol precipitation.
[0009] WO 2007 / 084773 discloses a dot blot analysis of infectious parvoviral vectors produced in insect cells without further specification.
[0010] Binny, CJ and Nathwani, AC disclosed an agarose gel analysis method for determining whether the genome packaged into the scAAV vector is a short double-stranded hairpin structure or a short ssDNA or a long non-folded ssDNA as expected (Meth. Mol. Biol. 891 (2012) 109-131).
[0011] US2021 / 0284699 discloses a qPCR method for analyzing rAAV particles that have been purified using a method comprising the following steps: (a) generating a viral particle extract comprising a plurality of rAAVs provided herein, wherein the viral particle extract comprises the supernatant of lysed production cells or a derivative thereof; (b) contacting the viral particle extract with an ionic detergent to generate a first mixture; (c) contacting the first mixture with an acid to generate a second mixture; (d) centrifuging the second mixture to generate a supernatant; (e) filtering the supernatant using one or more filters to generate a filtrate; and (f) performing one or more cycles of exchanging the filtrate buffer for a final storage buffer. Summary of the invention
[0012] This article reports a method for determining the number of viral genomic DNA copies in a sample, wherein the method comprises the following steps: incubating the sample with proteinase K and determining the number of viral genomic DNA copies by digital droplet polymerase chain reaction, wherein the sample does not contain DNA that is not encapsidated within viral particles, wherein the incubation with proteinase K is carried out in the presence of 0.05 (w / v)% to 1.5 (w / v)% sodium dodecyl sulfate.
[0013] A non-limiting number of aspects (independent subjects) and embodiments (dependent subjects) are:
[0014] 1. A method for determining the number of viral genomic DNA copies in a sample, wherein the method comprises the following steps:
[0015] - determining the viral genomic DNA copy number by digital droplet polymerase chain reaction,
[0016] wherein the sample does not contain DNA that is not encapsidated within a viral particle,
[0017] wherein the sample has not been incubated with a nuclease, and
[0018] wherein the sample has not been incubated with a protease.
[0019] 2. The method according to aspect 1, wherein the nuclease is a restriction enzyme.
[0020] 3. The method according to any one of Aspect 1 or Embodiment 2, wherein the nuclease is DNase I.
[0021] 4. The method according to any one of aspect 1 or embodiments 2 to 3, wherein the protease is proteinase K.
[0022] 5. A method for determining the number of viral genomic DNA copies in a sample, wherein the method
[0023] The following steps are involved:
[0024] - incubating the sample with proteinase K,
[0025] - Determine the viral genomic DNA copy number by digital droplet polymerase chain reaction.
[0026] 6. The method according to aspect 5, wherein the sample is a cell lysate.
[0027] 7. The method according to any one of Aspect 5 or Embodiment 6, wherein the sample is a lysed cell sample.
[0028] 8. The method according to embodiment 7, wherein the lysed cell sample has been obtained by lysing virus-producing cells with a detergent or by chemical means; optionally, cell debris has been removed from the lysed cell sample.
[0029] 9. The method of any one of aspect 5 or embodiments 6 to 8, wherein the sample comprises viral particles and does not contain DNA that is not encapsidated within the viral particles, wherein the viral DNA genome is encapsidated within the viral particles.
[0030] 10. A method for determining the number of viral genomic DNA copies in a sample, wherein the method comprises the following steps:
[0031] - incubating the sample with proteinase K,
[0032] - determining the viral genomic DNA copy number by digital droplet polymerase chain reaction,
[0033] wherein the sample does not contain DNA that is not encapsidated within a viral particle,
[0034] wherein said incubation with proteinase K is carried out in the presence of a detergent.
[0035] 11. The method according to aspect 10, wherein the detergent is sodium lauryl sulfate.
[0036] 12. The method according to any one of aspect 10 or embodiment 11, wherein the final concentration of the detergent during incubation with proteinase K is 0.05 (w / v) % to 1.5 (w / v) %
[0037] 13. The method of aspect 10 or any one of embodiments 11 to 12, wherein the final concentration of the detergent during incubation with proteinase K is about 0.1 (w / v) %.
[0038] 14. The method of aspect 10 or any one of embodiments 11 to 12, wherein the final concentration of the detergent during incubation with proteinase K is about 1 (w / v) %.
[0039] 15. The method according to any one of aspect 5 or aspect 10 or embodiments 6 to 9 or embodiments 11 to 14, wherein the method comprises the following steps:
[0040] - incubating the sample with a nuclease to obtain a digested sample,
[0041] - incubating the digested sample with proteinase K to obtain a proteinase K-incubated sample,
[0042] - Determining the viral genomic DNA copy number in the proteinase K-incubated sample by digital droplet polymerase chain reaction.
[0043] 16. The method of embodiment 15, wherein the digested sample is diluted up to 2.5-fold for the incubation with proteinase K.
[0044] 17. The method of any one of embodiments 15 to 16, wherein all of the digested sample is incubated with proteinase K.
[0045] 18. The method according to any one of aspect 1 or aspect 5 or aspect 10 or embodiments 2 to 4 or embodiments 6 to 9 or embodiments 11 to 17, wherein the digital droplet polymerase chain reaction comprises the following steps:
[0046] a) incubating the sample at about 95° C. for 10 minutes,
[0047] b) performing the following thermal cycle: incubating the sample at about 94° C. for 30 seconds, followed by incubating the sample at about 60° C. for 1 minute,
[0048] c) Repeat step b) 15 to 60 times,
[0049] d) A final extension step was performed at 98°C for 10 minutes.
[0050] 19. The method of embodiment 18, wherein steps a) and d) are performed with a temperature ramp of 2°C.
[0051] 20. The method of any one of Aspect 1 or Aspect 5 or Aspect 10 or Examples 2 to 4 or Examples 6 to 9 or Examples 11 to 19, wherein the sample is maintained at a temperature of 95°C or less.
[0052] 21. The method of any one of Aspect 1 or Aspect 5 or Aspect 10 or Examples 2 to 4 or Examples 6 to 9 or Examples 11 to 19, wherein the sample is not exposed to a temperature above 95°C.
[0053] 22. The method of any one of Aspect 1 or Aspect 5 or Aspect 10 or Examples 2 to 4 or Examples 6 to 9 or Examples 11 to 19, wherein the method is performed at a temperature up to 95°C, except for the final extension step of the digital droplet polymerase chain reaction.
[0054] 23. The method according to any one of aspect 5 or aspect 10 or embodiments 2 to 4 or embodiments 6 to 9 or embodiments 11 to 22, wherein the total amount of proteinase K employed in the incubation is 1 mU to 50 mU.
[0055] 24. The method according to any one of aspect 5 or aspect 10 or embodiments 2 to 4 or embodiments 6 to 9 or embodiments 11 to 23, wherein the total amount of proteinase K employed in the incubation is 10 mU to 40 mU.
[0056] 25. The method according to any one of aspect 5 or aspect 10 or embodiments 2 to 4 or embodiments 6 to 9 or embodiments 11 to 24, wherein the total amount of proteinase K employed in the incubation is 15 mU to 35 mU.
[0057] 26. The method according to any one of aspect 5 or aspect 10 or embodiments 2 to 4 or embodiments 6 to 9 or embodiments 11 to 25, wherein the total amount of proteinase K employed in the incubation is 20 mU to 32 mU.
[0058] 27. The method of any one of aspect 5 or aspect 10 or embodiments 2 to 4 or embodiments 6 to 9 or embodiments 11 to 26, wherein the total amount of proteinase K employed in the incubation is about 20 mU.
[0059] 28. The method of any one of aspect 5 or aspect 10 or embodiments 2 to 4 or embodiments 6 to 9 or embodiments 11 to 26, wherein the total amount of proteinase K employed in the incubation is about 32 mU.
[0060] 29. The method of any one of Aspect 1 or Aspect 5 or Aspect 10 or Examples 2 to 4 or Examples 6 to 9 or Examples 11 to 28, wherein the determination of the viral genomic DNA copy number is the quantification of the viral genomic DNA copy number.
[0061] 30. The method of any one of Aspect 1 or Aspect 5 or Aspect 10 or Examples 2 to 4 or Examples 6 to 9 or Examples 11 to 29, wherein the volume of the sample is about 10 μL.
[0062] 31. The method of any one of aspect 5 or aspect 10 or embodiments 2 to 4 or embodiments 6 to 9 or embodiments 11 to 30, wherein the incubation with proteinase K is performed in a total volume of 100 μL.
[0063] 32. The method of any one of embodiments 15 to 31, wherein the nuclease is DNase I.
[0064] 33. The method of any one of embodiments 15 to 32, wherein the total amount of nuclease employed in said incubation is about 5 U.
[0065] 34. The method of any one of embodiments 15 to 33, wherein said incubation with said nuclease is performed in a total volume of 50 μL.
[0066] 35. The method of any one of embodiments 15 to 34, wherein said incubation with said nuclease is performed at a final concentration of 40 mM Tris*HCl, 10 mM MgSO4, 1 mM CaCl2 at a pH of about 8.
[0067] 36. The method of any one of embodiments 15 to 35, wherein said incubation with said nuclease is at 37°C for 30 minutes.
[0068] 37. The method of embodiment 36, wherein the incubation is followed by inactivation of the nuclease at 95°C for 15 minutes.
[0069] 38. The method of any one of embodiments 15 to 37, wherein said incubation with proteinase K is performed at a final concentration of 20 mM Tris*HCl, 1 mM EDTA, 100 mM NaCl at a pH of about 8.
[0070] 39. The method of any one of embodiments 15 to 37, wherein said incubation with proteinase K is performed at a final concentration of 20 mM Tris*HCl, 1 mM EDTA, 100 mM NaCl at a pH of about 8.
[0071] 40. The method of any one of embodiments 15 to 37, wherein said incubation with proteinase K is performed at a final concentration of 20 mM Tris*HCl, 1 mM EDTA, 100 mM NaCl, 1 (w / v)% sodium dodecyl sulfate at a pH of about 8.
[0072] 41. The method of any one of embodiments 15 to 37, wherein the incubation with proteinase K is performed at a final concentration of 30 mM Tris*HCl, 5 mM MgSO4, 0.5 mM CaCl2, 0.5 mM EDTA, 50 mM NaCl, 0.1 (w / v)% sodium dodecyl sulfate at a pH of about 8.
[0073] 42. The method of any one of embodiments 15 to 41, wherein said incubation with proteinase K is at 50°C for 60 minutes.
[0074] 43. The method of embodiment 42, wherein said incubation is followed by inactivation of said protease at 95°C for 15 minutes.
[0075] 44. The method of any one of Aspect 1 or Aspect 5 or Aspect 10 or Examples 2 to 4 or Examples 7 to 9 or Examples 11 to 43, wherein the volume of sample is a cell lysate purified by affinity chromatography.
[0076] 45. The method of any one of Aspect 1 or Aspect 5 or Aspect 10 or Examples 2 to 4 or Examples 6 to 9 or Examples 11 to 43, wherein the method is performed in the absence of a precipitation step and / or glycogen. DETAILED DESCRIPTION
[0077] The present invention is based at least in part on the discovery that for AAV genome copy number determination, where the crude cell lysate sample contains AAV particles and also contains non-viral encapsidated DNA, the sample must be incubated prior to PCR with proteinase K. The presence of a detergent can further improve the determination.
[0078] The present invention is based, at least in part, on the discovery that for AAV genome copy number determination, where the purified sample contains AAV particles and is substantially free of non-viral encapsidated DNA, the sample must be incubated prior to PCR with proteinase K. Without being bound by theory, it is hypothesized that the detergent prevents the formation of aggregates of protein fragments and viral genomic DNA, which prevents subsequent amplification by polymerase chain reaction and thereby leads to an underestimation of the viral genome copy number in the sample.
[0079] The present invention is based at least in part on the discovery that for AAV genome copy number determination after sequential treatment with nucleases and proteases, the protease treatment must be performed in the presence of a detergent. Without being bound by this theory, it is hypothesized that the detergent prevents the formation of aggregates of protein fragments and viral genomic DNA, which prevents subsequent amplification by polymerase chain reaction and thereby leads to an underestimation of the viral genome copy number in the sample.
[0080] The present invention is further based, at least in part, on the discovery that for purified samples containing AAV particles and substantially free of non-viral encapsidated DNA, determination of AAV genome copy number must be performed in the absence of nuclease and protease pretreatment or incubation with proteinase K in the presence of a detergent prior to polymerase chain reaction. Without being bound by this theory, it is hypothesized that incubation of highly purified samples (i.e., containing no substantial amounts of non-viral encapsidated DNA) with nuclease alone or a combination of nuclease and protease in the absence of detergent results in aggregation and thereby artificially lowers the AAV genome copy number.
[0081] The present invention is further based, at least in part, on the discovery that for purified samples comprising AAV particles and substantially free of non-viral encapsidated DNA, determination of the AAV genome copy number must be performed at temperatures above 95° C. without a heat denaturation step. Without being bound by this theory, it is hypothesized that heat treatment of highly purified samples (i.e., not comprising substantial amounts of non-viral encapsidated DNA) at temperatures above 95° C. results in aggregation and thereby artificially reduces the AAV genome copy number.
[0082] The present invention is further based at least in part on the fact that low amounts of proteinase K in the presence of detergents are sufficient to make substantially all of the AAV genomes in a sample available for polymerase chain reaction and thereby determined / quantified. Without being bound by this theory, it is hypothesized that high concentrations of proteinase K interfere with the polymerase chain reaction and that the use of significantly reduced amounts (i.e., low amounts) of proteinase K results in an improvement in the polymerase chain reaction by reducing PCR inhibition. In particular, inhibition of the polymerase chain reaction by proteinaceous material in cell lysates of AAV producer cells can be reduced or even eliminated by incubation with proteinase K in the presence of detergents.
[0083] The present invention is further based, at least in part, on the discovery that for sequential incubations of crude cell lysate samples with nucleases and proteases, the sample should not be diluted after the nuclease incubation and the total volume of the incubation mixture should be used for the protease incubation step.
[0084] In general, the more pretreatment steps required before determining AAV genome copy number in a ddPCR approach, the higher the potential for contamination.
[0085] definition
[0086] Methods and techniques that can be used to practice the present invention are described in, for example, Ausubel, FM (ed.), Current Protocols in Molecular Biology, Volumes I to III (1997); Glover, ND and Hames, BD, eds., DNA Cloning: A Practical Approach, Volumes I and II (1985), Oxford University Press; Freshney, RI (ed.), Animal Cell Culture—a practical approach, IRL Press Limited (1986); Watson, JD et al., Recombinant DNA, Second Edition, CHSL Press (1992); Winnacker, EL, From Genes to Clones; NY, VCH Publishers (1987); Celis, J., ed., Cell Biology, Second Edition, Academic Press (1998); Freshney, RI, Culture of Animal Cells: A Manual of Basic Technique, Second Edition, Alan R. Liss, Inc., NY (1987).
[0087] It must be noted that, as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to "a cell" includes a plurality of such cells and equivalents thereof known to those skilled in the art, and so forth. Likewise, the terms "a", "one or more", and "at least one" may be used interchangeably herein. It should also be noted that the terms "comprising", "including", and "having" may be used interchangeably.
[0088] The term "AAV helper function" refers to AAV-derived coding sequences (proteins) that can be expressed to provide AAV gene products and AAV particles, which in turn act in trans to carry out productive AAV replication and packaging. Thus, AAV helper functions include AAV open reading frames (ORFs), including rep and cap, and others, such as AAP for certain AAV serotypes. The rep gene expression product has been shown to have many functions, including: recognition, binding and cleavage of the AAV origin of DNA replication; DNA helicase activity; and regulation of transcription from AAV (or other heterologous) promoters. The cap gene expression product (capsid) provides the necessary packaging function. AAV helper functions are used to supplement trans-AAV functions that are missing in the AAV vector genome.
[0089] The term "about" means a range of + / -20% of the value that follows. In certain embodiments, the term "about" means a range of + / -10% of the value that follows. In certain embodiments, the term "about" means a range of + / -5% of the value that follows.
[0090] The term "comprising" also encompasses the term "including".
[0091] The terms "empty capsid" and "empty particle" refer to an AAV particle that has an AAV protein capsid but lacks in whole or in part a nucleic acid encoding a protein or a nucleic acid transcribed into a target transcript flanked by the AAV ITRs (i.e., the vector). Thus, an empty capsid cannot function to transfer a nucleic acid encoding a protein or transcribed into a target transcript into a host cell.
[0092] The term "endogenous" means that something occurs naturally within a cell; is naturally produced by the cell; similarly, an "endogenous locus / cell endogenous locus" is a locus that occurs naturally in a cell.
[0093] As used herein, the term "exogenous" refers to a nucleotide sequence that is not derived from a specific cell, but is introduced into the cell by a DNA delivery method (e.g., by transfection, electroporation, or transduction by a viral vector). Therefore, an exogenous nucleotide sequence is an artificial sequence, wherein the artificiality can be derived from, for example, a combination of subsequences from different sources (e.g., a combination of a recombinase recognition sequence with an SV40 promoter and a coding sequence for a green fluorescent protein is an artificial nucleic acid) or from a sequence (e.g., a sequence encoding only the extracellular domain of a membrane-bound receptor or a cDNA) or a partial deletion, or a nuclear base mutation. The term "endogenous" refers to a nucleotide sequence derived from a cell. An "exogenous" nucleotide sequence can have an "endogenous" counterpart with the same base composition, but wherein the sequence becomes an "exogenous" sequence, for example, by being introduced into a cell via recombinant DNA technology.
[0094] An "isolated" composition is one that has been separated from one or more components of its natural environment. In some embodiments, the composition is purified to a purity greater than 95% or 99%, as determined by, for example, electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis, CE-SDS) or chromatography (e.g., size exclusion chromatography or ion exchange or reversed phase HPLC). For a review of methods for assessing, for example, antibody purity, see Flatman, S. et al., J. Chrom. B 848 (2007) 79-87.
[0095] An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from one or more components of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in cells that normally contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.
[0096] An "isolated" polypeptide or antibody is one that has been separated from one or more components of its natural environment.
[0097] The term "mammalian cell comprising an exogenous nucleotide sequence" encompasses cells into which one or more exogenous nucleic acids have been introduced, including the offspring of such cells. These can serve as the starting point for further genetic modification. Therefore, the term "mammalian cell comprising an exogenous nucleotide sequence" encompasses cells comprising an exogenous nucleotide sequence integrated at a single site in the locus of the mammalian cell genome, wherein the exogenous nucleotide sequence at least comprises a first recombination recognition site and a second recombination recognition site (these recombination recognition sites are different) flanking at least one first selection marker. In certain embodiments, the mammalian cell comprising an exogenous nucleotide sequence is a cell comprising an exogenous nucleotide sequence integrated at a single site in the locus of the cell genome, wherein the exogenous nucleotide sequence comprises a first recombination recognition sequence and a second recombination recognition sequence flanking at least one first selection marker, and a third recombination recognition sequence between the first recombination recognition sequence and the second recombination recognition sequence, and all recombination recognition sequences are different.
[0098] "Mammalian cells comprising exogenous nucleotide sequences" and "recombinant cells" are both "transformed cells". The term includes the primary transformed cell and progeny derived therefrom, without regard to the number of passages. Progeny may, for example, not be completely identical to the nucleic acid content of the parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as in the originally transformed cell are encompassed.
[0099] "Nucleic acid encoding AAV packaging proteins" generally refers to one or more nucleic acid molecules, which include nucleotide sequences that provide AAV functions deleted from AAV vectors, and the nucleic acid molecules are used to produce transduction-active recombinant AAV particles. Nucleic acids encoding AAV packaging proteins are generally used to provide expression of AAV rep and / or cap genes to supplement the missing AAV functions required for AAV replication; however, the nucleic acid construct lacks AAV ITR and can neither replicate nor package itself. Nucleic acids encoding AAV packaging proteins can be in the form of plasmids, phages, transposons, cosmids, viruses or particles. Many nucleic acid constructs have been described, such as the commonly used plasmids pAAV / Ad and pIM29+45, which encode both rep gene expression products and cap gene expression products. See, for example, Samulski et al., J. Virol. 63 (1989) 3822-3828; and McCarty et al., J. Virol. 65 (1991) 2936-2945. Many plasmids encoding rep and / or cap gene expression products have been described (e.g., US 5,139,941 and US 6,376,237). Any of these nucleic acids encoding AAV packaging proteins may contain a DNA element or nucleic acid according to the present invention.
[0100] The term "nucleic acid encoding an auxiliary protein" generally refers to one or more nucleic acid molecules that include nucleotide sequences encoding proteins and / or RNA molecules that provide adenoviral auxiliary functions. Plasmids with nucleic acids encoding auxiliary proteins can be transfected into suitable cells, where the plasmid is then able to support the production of AAV particles in the cells. Any of these nucleic acids encoding auxiliary proteins may comprise a DNA element or nucleic acid according to the present invention. The term explicitly excludes infectious viral particles as they occur in nature, such as adenovirus, herpes virus or vaccinia virus particles.
[0101] As used herein, the term "operably connected" refers to the juxtaposition of two or more components, wherein the relationship of these components allows them to play a role in an expected manner. For example, if a promoter and / or enhancer plays a role in regulating the transcription of a coding sequence / open reading frame / gene, the promoter and / or enhancer are operably connected to the coding sequence / open reading frame / gene. In certain embodiments, the DNA sequence of "operably connected" is adjacent. In certain embodiments, for example, when two protein coding regions (such as a secretory leader and a polypeptide) must be joined, these sequences are adjacent and in the same reading frame. In certain embodiments, the promoter that is operably connected is located upstream of the coding sequence / open reading frame / gene and can be adjacent to the coding sequence / open reading frame / gene. In certain embodiments, for example, about the enhancer sequence regulating the expression of the coding sequence / open reading frame / gene, these two components can be operably connected, but not adjacent. If an enhancer increases the transcription of the coding sequence / open reading frame / gene, the enhancer is operably connected to the coding sequence / open reading frame / gene. An operably linked enhancer may be located upstream, within, or downstream of a coding sequence / open reading frame / gene and may be located at a considerable distance from the promoter of the coding sequence / open reading frame / gene.
[0102] The term "packaging protein" refers to non-AAV derived viral and / or cellular functions on which AAV replication depends. Thus, the term embodies proteins and RNAs required for AAV replication, including those involved in AAV gene transcriptional activation, stage-specific AAV mRNA splicing, AAV DNA replication, Cap expression product synthesis, and AAV capsid assembly. Virus-based helper functions can be derived from any of the known helper viruses, such as adenovirus, herpes virus (except herpes simplex virus type I) and vaccinia virus.
[0103] As used herein, "AAV packaging proteins" refer to AAV-derived sequences that act in trans to carry out productive AAV replication. Therefore, AAV packaging proteins are encoded by the major AAV open reading frames (ORFs), rep and cap. The rep protein has been shown to have many functions, including: recognition, binding and cleavage of the AAV origin of DNA replication; DNA helicase activity; and regulation of transcription from AAV (or other heterologous) promoters. The cap (capsid) protein provides the necessary packaging function. AAV packaging proteins are used herein to supplement the trans-AAV functions missing in AAV vectors.
[0104] "Plasmid" is a form of nucleic acid or polynucleotide, which usually has additional elements for plasmid expression (e.g., transcription, replication, etc.) or proliferation (replication). As used herein, plasmid can also be used to refer to such nucleic acid or polynucleotide sequences. Therefore, in all aspects, the compositions and methods of the present invention are applicable to nucleic acids, polynucleotides and plasmids, such as for the production of cells for producing viral (e.g., AAV) vectors, the production of viral (e.g., AAV) particles, the production of cell culture media containing viral (e.g., AAV) particles, etc.
[0105] As used herein, the term "recombinant cell" refers to a cell that has been genetically modified, such as, for example, a cell that expresses a polypeptide of interest or produces rAAV particles of interest and can be used to produce the polypeptide of interest or rAAV particles of interest on any scale. For example, a "mammalian cell comprising an exogenous nucleotide sequence" that has undergone recombinase-mediated cassette exchange (RMCE) and has thus introduced the coding sequence of the polypeptide of interest into the host cell genome is a "recombinant cell". Although the cell is still capable of further RMCE reactions, it is not desirable to do so.
[0106] "Recombinant AAV vectors" are derived from the wild-type genome of a virus (such as AAV) by using molecular methods to remove the wild-type genome from the virus (e.g., AAV) and replace the wild-type genome with a non-native nucleic acid (such as a nucleic acid transcribed into a transcript or encoding a protein). For AAV, one or two inverted terminal repeat (ITR) sequences of the wild-type AAV genome are usually retained in the recombinant AAV vector. "Recombinant" AAV vectors are distinguished from the wild-type viral AAV genome because all or part of the viral genome has been replaced with a non-native (i.e., heterologous) sequence relative to the viral genomic nucleic acid. Therefore, the incorporation of non-native sequences defines a viral vector (e.g., AAV) as a "recombinant" vector, which in the case of AAV can be referred to as a "rAAV vector."
[0107] Recombinant vector (e.g., AAV) sequences can be packaged - referred to herein as "particles" - for subsequent cell infection (transduction) ex vivo, in vitro or in vivo. When recombinant vector sequences are encapsulated or packaged into AAV particles, the particles may also be referred to as "rAAV". Such particles include proteins that encapsulate or package the vector genome. Specific examples include viral envelope proteins, and in the case of AAV, capsid proteins such as AAV VP1, VP2 and VP3.
[0108] As used herein, the term "selection marker" refers to a gene that allows specific selection or exclusion of cells carrying the gene in the presence of a corresponding selective agent. For example, but not limited to, a selection marker can allow positive selection of host cells transformed with the selection marker gene in the presence of a corresponding selective agent (selective culture conditions); untransformed host cells will not be able to grow or survive under the selective culture conditions. Selection markers can be positive, negative or bifunctional. Positive selection markers can allow selection of cells carrying the marker, while negative selection markers can allow selective elimination of cells carrying the marker. Selection markers can confer resistance to drugs, or compensate for metabolic or catabolism defects in host cells. In prokaryotic cells, genes that confer resistance to ampicillin, tetracycline, kanamycin or chloramphenicol, as well as other genes, can be used. Resistance genes that can be used as selectable markers in eukaryotic cells include, but are not limited to, genes for aminoglycoside phosphotransferases (APHs) (e.g., hygromycin phosphotransferase (HYG), neomycin and G418 APH), dihydrofolate reductase (DHFR), thymidine kinase (TK), glutamine synthetase (GS), asparagine synthetase, tryptophan synthetase (indole), histidinol dehydrogenase (histidinol D), and genes encoding resistance to puromycin, blasticidin, bleomycin, phleomycin, chloramphenicol, Zeocin and mycophenolic acid. Additional marker genes are described in WO 92 / 08796 and WO 94 / 28143.
[0109] In addition to facilitating selection in the presence of a corresponding selective agent, a selectable marker may alternatively be a molecule that is not normally present in cells, such as green fluorescent protein (GFP), enhanced GFP (eGFP), synthetic GFP, yellow fluorescent protein (YFP), enhanced YFP (eYFP), cyan fluorescent protein (CFP), mPlum, mCherry, tdTomato, mStrawberry, J-red, DsRed monomer, mOrange, mKO, mCitrine, Venus, YPet, Emerald, CyPet, mCFPm, Cerulean, and T-Sapphire. Cells expressing such a molecule can be distinguished from cells not containing the gene, for example, by detecting fluorescence emitted by the encoded polypeptide or the absence of such fluorescence, respectively.
[0110] As used herein, the term "serotype" is a distinction based on serologically different AAV capsids. Serological distinctiveness is determined based on the lack of cross-reactivity between antibodies to one AAV compared to antibodies to another AAV. Such cross-reactivity differences are usually due to differences in capsid protein sequences / antigenic determinants (e.g., due to differences in VP1, VP2, and / or VP3 sequences of AAV serotypes). Although AAV variants, including capsid variants, may be serologically indistinguishable from reference AAV or other AAV serotypes, they differ in at least one nucleotide or amino acid residue compared to the reference AAV serotype or other AAV serotypes.
[0111] Under the traditional definition, serotype refers to the target virus that has been tested for serum, which has specificity for neutralizing activity to all existing and characterized serotypes, and no antibodies to neutralize the target virus are found. With the discovery of more naturally occurring virus isolates and / or the generation of capsid mutants, there may or may not be serological differences with any of the currently existing serotypes. Therefore, in the case where a new virus (such as AAV) does not have serological differences, the new virus (such as AAV) will be a subgroup or variant of the corresponding serotype. In many cases, serological tests for neutralizing activity have not yet been performed on mutant viruses with modified capsid sequences to determine whether they have another serotype according to the traditional definition of serotype. Therefore, for convenience and to avoid duplication, the term "serotype" refers broadly to serologically different viruses (such as AAV) and serologically no different viruses (such as AAV), which may be within a subgroup or variant of a given serotype.
[0112] The terms "transduction" and "transfection" refer to the introduction of molecules such as nucleic acids (viral vectors, plasmids) into cells. When exogenous nucleic acids have been introduced into the cell membrane, the cell has been "transduced" or "transfected". Therefore, a "transduced cell" is a cell into which a "nucleic acid" or "polynucleotide" has been introduced, or its progeny into which an exogenous nucleic acid has been introduced. In a specific embodiment, a "transduced" cell (e.g., in a mammal, such as a cell or a tissue or organ cell) has a genetic change after the incorporation of an exogenous molecule such as a nucleic acid (e.g., a transgene). A "transduced" cell can reproduce and transcribe the introduced nucleic acid and / or express a protein.
[0113] In "transduced" or "transfected" cells, the nucleic acid (viral vector, plasmid) may or may not be integrated into the genomic nucleic acid. If the introduced nucleic acid is integrated into the nucleic acid (genomic DNA) of the recipient cell or organism, it can be stably maintained in the cell or organism and further transmitted to or inherited by the daughter cells or organisms of the recipient cell or organism. Finally, the introduced nucleic acid may be present extrachromosomally in the recipient cell or host organism, or only transiently. Many techniques are known, for example, see, Graham et al., Virology 52 (1973) 456; Sambrook et al. (1989) Molecular Cloning, a laboratory manual, Cold Spring Harbor Laboratories, New York; Davis et al. (1986) Basic Methods in Molecular Biology, Elsevier; and Chu et al., Gene 13 (1981) 197. Such techniques can be used to introduce one or more exogenous DNA moieties into suitable host cells.
[0114] The term "transgene" is used herein for convenience to refer to a nucleic acid that is intended to be or has been introduced into a cell or organism. A transgene includes any nucleic acid, such as a gene, that is transcribed into a transcript or encodes a polypeptide or protein.
[0115] "Vector" refers to a portion of a recombinant plasmid sequence that is ultimately packaged or encapsulated directly or in the form of a single strand or RNA to form a virus (e.g., AAV) particle. In the case where a recombinant plasmid is used to construct or manufacture a recombinant virus particle, the virus particle does not include a "plasmid" portion that does not correspond to the vector sequence of the recombinant plasmid. This non-vector portion of the recombinant plasmid is called a "plasmid backbone," which is important for cloning and amplification of the plasmid, a process required for propagation and recombinant virus production, but it itself is not packaged or encapsulated into a virus (e.g., AAV) particle. Therefore, "vector" refers to a nucleic acid packaged or encapsulated by a virus particle (e.g., AAV).
[0116] Recombinant cells
[0117] In general, for efficient and large-scale production of a target protein compound, such as, for example, rAAV particles or therapeutic polypeptides, cells that express and, if possible, also secrete the protein compound are necessary. Such cells are referred to as "recombinant cells" or "recombinant production cells".
[0118] To generate a "recombinant producer cell", suitable mammalian cells are transfected with the desired nucleic acid sequence encoding the protein compound of interest. Additional auxiliary polypeptides may need to be transfected.
[0119] In order to generate stable recombinant production cells, a second step is then performed in which single cells that stably express the protein compound of interest are selected. This can be done, for example, based on the co-expression of a selection marker that has been co-transfected with the nucleic acid sequence encoding the protein compound of interest, or on the expression of the protein compound itself.
[0120] For expressing coding sequence, i.e. open reading frame, additional regulatory elements are needed, such as promoter and polyadenylation signal (sequence). Therefore, open reading frame is operably connected to the additional regulatory elements for transcription. This can be achieved by being integrated into the so-called expression cassette. The minimum regulatory elements required for the expression cassette to work in mammalian cells are the promoter working in the mammalian cell, the promoter is located at the upstream of the open reading frame, i.e. 5', and the polyadenylation signal (sequence) working in the mammalian cell, the polyadenylation signal is located at the downstream of the open reading frame, i.e. 3'. In addition, the terminator sequence may be present in the 3' of the polyadenylation signal (sequence). For expression, promoter, open reading frame / coding region and polyadenylation signal sequence must be arranged in an operably connected form.
[0121] Similarly, nucleic acids that are transcribed into RNA encoding non-proteins are referred to as "RNA genes". Also for the expression of RNA genes, additional regulatory elements are required, such as promoters and transcription termination signals or polyadenylation signals (sequences). The nature and positioning of such elements depend on the RNA polymerase intended to drive RNA gene expression. Therefore, RNA genes are also typically integrated into expression cassettes.
[0122] If the target protein compound is an AAV particle, which is composed of different (monomeric) capsid polypeptides and single-stranded DNA molecules, and other adenoviral helper functions are additionally required for production and packaging, multiple expression cassettes are required, which differ in the open reading frame / coding sequence contained. In this case, at least an expression cassette is required for each of the transgene, the different polypeptides forming the capsid of the AAV vector, the required helper functions and the VA RNA. Thus, a separate expression cassette is required for each of the helper E1A, E1B, E2A, E4orf6, VA RNA, rep and cap genes.
[0123] As outlined in the previous paragraph, respectively, the more complex or additionally required auxiliary polypeptide and / or RNA quantity of the target protein compound is, the higher the number of required different expression cassettes is. The total size of nucleic acid is also inherently related to the number of expression cassettes. However, there is a practical upper limit to the transferable nucleic acid size, which ranges from about 15kbps (kilobase pairs). Exceeding this limit, processing and processing efficiency will significantly decrease. This problem can be solved by using two or more independent plasmids. Thus, different expression cassettes are assigned to different plasmids, and each plasmid only comprises some of the expression cassettes thus.
[0124] In certain embodiments of all aspects and embodiments, each of the expression cassettes comprises a promoter, an open reading frame / coding sequence or an RNA gene and a polyadenylation signal sequence and / or a terminator sequence in the 5' to 3' direction. In certain embodiments, the open reading frame encodes a polypeptide and the expression cassette comprises a polyadenylation signal sequence with or without an additional terminator sequence. In certain embodiments, the expression cassette comprises an RNA gene, the promoter is a type 2 Pol III promoter and there is a polyadenylation signal sequence or a polyU terminator. See, e.g., Song et al. Biochemical and Biophysical Research Communications 323 (2004) 573–578. In certain embodiments, the expression cassette comprises an RNA gene, the promoter is a type 2 Pol III promoter and a polyU terminator sequence.
[0125] In certain embodiments of all aspects and embodiments, the open reading frame encodes a polypeptide, the promoter is human CMV promoter with or without intron A, the polyadenylation signal sequence is the bGH (bovine growth hormone) polyA signal sequence, and the terminator is hGT (human gastrin terminator).
[0126] In certain embodiments of all aspects and embodiments, the promoter is the human CMV promoter with intron A, the polyadenylation signal sequence is the bGH polyadenylation signal sequence and the terminator is hGT, except for the expression cassette for the RNA gene and the expression cassette for the selection marker, wherein for the selection marker, the promoter is the SV40 promoter and the polyadenylation signal sequence is the SV40 polyadenylation signal sequence and the terminator is not present, and wherein for the RNA gene, the promoter is the wild-type type 2 polymerase III promoter and the terminator is a polymerase II or III terminator.
[0127] Adeno-associated virus (AAV)
[0128] For a general review of AAV and adenovirus or herpes helper functions, see Berns and Bohensky, Advances in Virus Research, Academic Press., 32 (1987) 243-306. The genome of AAV is described in Srivastava et al., J. Virol., 45 (1983) 555-564. Design considerations for constructing recombinant AAV vectors are described in US 4,797,368 (see also WO 93 / 24641). Other references describing AAV vectors are West et al., Virol. 160 (1987) 38-47; Kotin, Hum. Gene Ther. 5 (1994) 793-801; and Muzyczka J. Clin. Invest. 94 (1994) 1351. The construction of recombinant AAV vectors is described in US 5,173,414; Lebkowski et al., Mol. Cell. Biol. 8 (1988) 3988-3996; Tratschin et al., Mol. Cell. Biol. 5 (1985) 3251-3260; Tratschin et al., Mol. Cell. Biol., 4 (1994) 2072-2081; Hermonat and Muzyczka Proc. Natl. Acad. Sci. USA 81 (1984) 6466-6470; Samulski et al. J. Virol. 63 (1989) 3822-3828
[0129] Adeno-associated virus (AAV) is a replication-defective parvovirus. It can only replicate in cells where certain viral functions are provided by a co-infecting helper virus, such as adenovirus, herpes virus, and in some cases poxvirus, such as vaccinia. Nevertheless, AAV can replicate in almost any cell line of human, simian or rodent origin, provided that appropriate helper virus functions are present.
[0130] If helper viral genes are not present, AAV establishes latency in its host cells. Its genome integrates into a specific site in chromosome 19 [(Chr)19(q13.4)], called adeno-associated virus integration site 1 (AAVS1). For specific serotypes, such as AAV-2, other integration sites have been found, such as, for example, on chromosome 5 [(Chr)5(p13.3)], called AAVS2, and on chromosome 3 [(Chr)3(p24.3)], called AAVS3.
[0131] AAV is divided into different serotypes. These are assigned based on parameters such as hemagglutination, tumorigenicity, and DNA sequence homology. To date, more than 10 different serotypes and more than a hundred sequences corresponding to different branches of AAV have been identified.
[0132] The capsid protein type and symmetry determine the tissue tropism of the corresponding AAV. For example, AAV-2, AAV-4, and AAV-5 are specific for the retina, AAV-2, AAV-5, AAV-8, AAV-9, and AAVrh-10 are specific for the brain, AAV-1, AAV-2, AAV-6, AAV-8, and AAV-9 are specific for cardiac tissue, AAV-1, AAV-2, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, and AAV-10 are specific for the liver, and AAV-1, AAV-2, AAV-5, and AAV-9 are specific for the lung.
[0133] Pseudotyping refers to a process that involves cross-packaging of the AAV genome between different serotypes, i.e., the genome is packaged with capsid proteins of different origin.
[0134] The wild-type AAV genome size is about 4.7 kb. The AAV genome further comprises two overlapping genes, called rep and cap, which contain multiple open reading frames (see, for example, Srivastava et al., J. Viral., 45 (1983) 555-564; Hermonat et al., J. Viral. 51 (1984) 329-339; Tratschin et al., J. Virol., 51 (1984) 611-619). The open reading frame encoding the Rep protein provides four proteins of different sizes, which are called Rep78, Rep68, Rep52 and Rep40. These are involved in the replication, rescue and integration of AAV. The open reading frame encoding the Cap protein provides four proteins, called VP1, VP2, VP3 and AAP. VP1, VP2 and VP3 are part of the protein capsid of the AAV particle. The combined rep and cap open reading frames are flanked by so-called inverted terminal repeats (ITRs) at their 5' and 3' ends. For replication, AAV requires, in addition to the Rep and Cap proteins, the products of the adenoviral genes E1A, E1B, E4orf6, E2A and VA or the corresponding factors of another helper virus.
[0135] For example, in the case of AAV of serotype 2 (AAV-2), each ITR has a length of 145 nucleotides and is flanked by a coding sequence region of about 4470 nucleotides. Of the 145 nucleotides of the ITR, 125 nucleotides have a palindromic sequence and can form a T-shaped hairpin structure. This structure functions as a primer during viral replication. The remaining 20 non-paired nucleotides are represented as D sequences.
[0136] The AAV genome contains three transcription promoters P5, P19 and P40 (Laughlin et al., Proc. Natl. Acad. Sci. USA 76 (1979) 5567-5571) for the expression of rep and cap genes.
[0137] ITR sequence must be present in the coding region in cis. ITR provides a functional origin of replication (ori), is integrated into the target cell genome required signal, and effectively excised and rescued from the host cell chromosome or recombinant plasmid. ITR further comprises an origin of replication-like element, such as Rep protein binding site (RBS) and terminal resolution site (TRS). It has been found that ITR itself can have the function of a transcription promoter in an AAV vector (Flotte et al., J.Biol.Chem.268 (1993) 3781-3790; Flotte et al., Proc.Natl.Acad.Sci.USA 93 (1993) 10163-10167).
[0138] The trans organization of the rep and cap gene products is required for the replication and encapsidation of the viral single-stranded DNA genome, respectively.
[0139] The rep locus comprises two internal promoters, called P5 and P19. It comprises open reading frames for four kinds of proteins. Promoter P5 is operably connected to a nucleotide sequence providing a non-spliced 4.2kb mRNA encoding Rep protein Rep78 (chromatin nickase that blocks the cell cycle) and a spliced 3.9kb mRNA encoding Rep protein Rep68 (site-specific endonuclease). Promoter P19 is operably connected to a nucleotide sequence providing a non-spliced mRNA encoding Rep protein Rep52 and a spliced 3.3kb mRNA encoding Rep protein Rep40 (DNA helicase for accumulation and packaging).
[0140] The two larger Rep proteins, Rep78 and Rep68, are essential for AAV duplex DNA replication, whereas the smaller Rep proteins, Rep52 and Rep40, appear to be essential for progeny single-stranded DNA accumulation (Chejanovsky & Carter, Virology 173 (1989) 120-128).
[0141] The larger Rep proteins Rep68 and Rep78 can specifically bind to the hairpin conformation of AAV ITR. They exhibit defined enzymatic activity, which is required for resolving replication at the AAV termini. Expression of Rep78 or Rep68 may be sufficient for the formation of infectious particles (Holscher, C. et al. J. Virol. 68 (1994) 7169-7177 and 69 (1995) 6880-6885).
[0142] All Rep proteins, primarily Rep78 and Rep68, are believed to exhibit regulatory activities such as induction and repression of AAV genes and inhibition of cell growth (Tratschin et al., Mol. Cell. Biol. 6 (1986) 2884-2894; Labow et al., Mol. Cell. Biol., 7 (1987) 1320-1325; Khleif et al., Virology, 181 (1991) 738-741).
[0143] Recombinant overexpression of Rep78 produces a phenotype of reduced cell growth caused by inducing DNA damage, thereby arresting host cells in the S phase, thereby promoting latent infection of the virus (Berthet, C. et al., Proc. Natl. Acad. Sci. USA 102 (2005) 13634-13639).
[0144] Tratschin et al. reported that the P5 promoter is negatively autoregulated by Rep78 or Rep68 (Tratschin et al., Mol. Cell. Biol. 6 (1986) 2884-2894). Due to the toxic effects of Rep protein expression, it has been reported that after stable integration of AAV, expression for some cell lines is only very low (see, e.g., Mendelson et al., Virol. 166 (1988) 154-165).
[0145] The cap locus contains a promoter, called P40. The promoter P40 is operably linked to a nucleic acid sequence that provides 2.6 kb mRNA, which encodes the Cap proteins VP1 (87 kDa, non-spliced mRNA transcripts), VP2 (72 kDa, from spliced mRNA transcripts) and VP3 (61 kDa, from alternative start codons) by alternative splicing and using alternative start codons. VP1 to VP3 constitute the components of the viral capsid. The capsid has the function of binding to cell surface receptors and allowing intracellular transport of the virus. VP3 accounts for about 90% of the total protein of the viral particle. However, all three proteins are essential for effective capsid production.
[0146] Inactivation of all three capsid proteins VP1 to VP3 reportedly prevents the accumulation of single-stranded progeny AAV DNA. Mutations at the amino terminus of VP1 (“Lip negative” or “Inf negative”) still allow single-stranded DNA to assemble into viral particles, thereby greatly reducing infectious titers.
[0147] The AAP open reading frame encodes the assembly activation protein (AAP). It is about 22 kDa in size and transports native VP protein to the nucleolar region for capsid assembly. This open reading frame is located upstream of the VP3 protein coding sequence.
[0148] A single AAV particle contains only one single-stranded DNA molecule. This can be either the "plus" strand or the "minus" strand. AAV virus particles containing DNA molecules are infectious. Within infected cells, the parental infectious single strand is converted to a double strand and subsequently amplified. Amplification produces a large number of double-stranded DNA molecules, which displace the single strand and are packaged into capsids.
[0149] Adeno-associated virus (AAV) vectors can transduce both dividing and quiescent cells. It can be assumed that transgenes introduced into target cells using AAV vectors will be expressed long term. One disadvantage of using AAV vectors is that the size of the transgene that can be introduced into cells is limited.
[0150] Viral vectors such as parvovirus particles, including AAV serotypes and variants thereof, provide a way to deliver nucleic acids to protein-encoding cells in vitro, in vitro, and in vivo, so that the cells express the encoded protein. AAV is a virus that can be used as a gene therapy vector because they can penetrate cells and introduce nucleic acids / genetic material so that nucleic acids / genetic material can be stably maintained in cells. In addition, for example, these viruses can introduce nucleic acids / genetic material into specific sites. Since AAV is not related to human pathogenic diseases, AAV vectors are able to deliver heterologous polynucleotide sequences (e.g., therapeutic proteins and agents) to human patients without causing substantial AAV pathogenesis or disease.
[0151] Viral vectors that can be used include, but are not limited to, adeno-associated virus (AAV) particles of various serotypes (eg, AAV-1 to AAV-12, etc.) and hybrid / chimeric AAV particles.
[0152] Advantageously, AAV particles can be used as vehicles for efficient gene delivery. Such particles have many characteristics required for such applications, including tropism for dividing and non-dividing cells. Early clinical experience with these vectors also showed no persistent toxicity, and the immune response was small or undetectable. AAV is known to infect a variety of cell types in vivo and in vitro through receptor-mediated endocytosis or through transcytosis. These vector systems have been tested in humans targeting retinal epithelium, liver, skeletal muscle, airways, brain, joints, and hematopoietic stem cells.
[0153] Recombinant AAV particles generally do not include viral genes associated with pathogenesis. Such vectors generally have one or more of the wild-type AAV genes that are completely or partially deleted, such as rep and / or cap genes, but retain at least one functional flanking ITR sequence, which is necessary for rescuing, replicating, and packaging the recombinant vector into AAV particles. For example, only the essential parts of the vector are included, such as ITR and LTR elements, respectively. Therefore, the AAV vector genome will include cis sequences (e.g., functional ITR sequences) required for replication and packaging.
[0154] Recombinant AAV vectors and methods and uses thereof include any viral strain or serotype. As a non-limiting example, the recombinant AAV vector can be based on any AAV genome, such as, for example, AAV-1, -2, -3, -4, -5, -6, -7, -8, -9, -10, -11, -12, 2i8, AAV rh74 or AAV 7m8. Such vectors can be based on the same strain or serotype (or subgroup or variant), or different from each other. As a non-limiting example, a recombinant AAV vector based on a serotype genome can be the same as one or more of the capsid proteins that package the vector. In addition, the recombinant AAV vector genome can be based on an AAV (e.g., AAV2) serotype genome that is different from one or more of the AAV capsid proteins that package the vector. For example, the AAV vector genome can be based on AAV2, and at least one of the three capsid proteins can be AAV1, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV-2i8, AAV rh74, AAV 7m8 or a variant thereof. AAV variants include variants and chimeras of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV-2i8, AAV rh74 and AAV 7m8 capsids.
[0155] In certain embodiments of all aspects and embodiments, adeno-associated virus (AAV) vectors include AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV-2i8, AAV rh74 and AAV7m8 and variants thereof (e.g., capsid variants, such as amino acid insertions, additions, substitutions and deletions), for example, as shown in WO 2013 / 158879, WO 2015 / 013313 and US2013 / 0059732 (disclosing LK01, LK02, LK03, etc.).
[0156] AAV and AAV variant (e.g., capsid variant) serotypes (e.g., VP1, VP2 and / or VP3 sequences) may or may not be different from other AAV serotypes, including, for example, AAV1-AAV12 (e.g., different from the VP1, VP2 and / or VP3 sequences of any of the AAV1 to AAV12 serotypes).
[0157] In certain embodiments of all aspects and embodiments, the AAV particles associated with a reference serotype have a polynucleotide, polypeptide, or subsequence thereof that comprises or consists of a sequence that is at least 80% or more (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, etc.) identical to one or more AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV-2i8, AAV rh74, or AAV 7m8 (e.g., such as ITRs, or VP1, VP2, and / or VP3 sequences).
[0158] The compositions, methods and uses of the present invention include AAV sequences (polypeptides and nucleotides) and subsequences thereof that exhibit less than 100% sequence identity to a reference AAV serotype (such as AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV-2i8, AAV rh74 or AAV7m8), but are different and not identical to known AAV genes or proteins (such as AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV-2i8, AAV rh74 or AAV 7m8 genes or proteins, etc.). In certain embodiments of all aspects and embodiments, the AAV polypeptide or a subsequence thereof comprises or consists of a sequence that is at least 75% or more identical (e.g., 80%, 85%, 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, etc., up to 100% identical) to any reference AAV sequence or a subsequence thereof, such as AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV-2i8, AAV rh74 or AAV 7m8 (e.g., VP1, VP2 and / or VP3 capsid or ITRs). In certain embodiments, the AAV variant has 1, 2, 3, 4, 5, 5 to 10, 10 to 15, 15 to 20, or more amino acid substitutions.
[0159] Recombinant AAV particles, including AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV-2i8, AAV rh74 or AAV 7m8, as well as variants, related, hybrid and chimeric sequences, can be constructed using recombinant techniques known to those skilled in the art to include one or more nucleic acid sequences (transgenes) flanked by one or more functional AAV ITR sequences.
[0160] Recombinant particles (e.g., rAAV particles) can be incorporated into pharmaceutical compositions. Such pharmaceutical compositions are particularly useful for in vivo or ex vivo administration and delivery to a subject. In certain embodiments, the pharmaceutical composition contains a pharmaceutical carrier or excipient. Such excipients include any medicament that does not itself induce an immune response that is harmful to the individual receiving the composition and can be administered without excessive toxicity.
[0161] Protocols for generating adenoviral vectors have been described in US 5,998,205; US 6,228,646; US 6,093,699; US 6,100,242; WO 94 / 17810 and WO 94 / 23744, the entire contents of which are incorporated herein by reference.
[0162] Specific embodiments of the method according to the present invention
[0163] In order to allow for viral genome copy determination, the viral genome must be made accessible, i.e. the shielding capsid must be opened. For this purpose, heat denaturation is convenient and commonly used. However, it has been found that heat denaturation can lead to an artificial decrease in viral genome copy number.
[0164] The inventors have demonstrated that heat denaturation at temperatures above 95°C, such as, for example, 98°C, results in a defined reduction in the number of viral genome copies. This has been demonstrated using the ATCC AAV2 standard VR-1616. The nominal viral genome copy number (vgcn) of the batch used in the experiment was 3.28*10E10 vg / mL. The results are shown in Table 1 below.
[0165] Table 1:
[0166] condition Absolutely vgcn Relative vgcn No pre-processing 2.735-3.306*10E10 / mL 83-101% Heat denaturation, 98°C, 10 min 1.012*10E10 / mL 31%
[0167] Likewise, the inventors have demonstrated that incubation with proteinase K (PK) in aqueous or buffered solutions in the absence of detergents also results in a defined reduction in the number of viral copy genomes. This has been demonstrated using ATCC AAV2 standard VR-1616. The nominal viral genome copy number (vgcn) of the batch used in the experiment was 3.28*10E10 vg / mL. The results are shown in Table 2 below.
[0168] Table 2:
[0169]
[0170] In combination, the inventors have demonstrated that heat denaturation at temperatures above 95°C, such as, for example, 98°C, even in combination with incubation with proteinase K (PK) in a buffer without detergent, leads to a defined reduction in the number of viral copy genomes. This has been exemplified using the ATCC AAV2 standard VR-1616. The nominal viral genome copy number (vgcn) of the batch used in the experiment was 3.28*10E10 vg / mL. The results are shown in Table 3 below.
[0171] Table 3:
[0172]
[0173] The inventors have now discovered that a reduction in the number of viral genome copies determined can be overcome by incubating with proteinase K in the presence of sodium dodecyl sulfate (SDS). This was demonstrated in this example using ATCC AAV2 standard VR-1616. The nominal viral genome copy number (vgcn) of the batch used in the experiment was 3.28*10E10 vg / mL. The results are shown in Table 4 below.
[0174] Table 4:
[0175]
[0176] The recoveries obtained under the conditions of Table 4 met the acceptance criteria for assay procedure validation according to EMA and FDA guidelines, i.e., within + / - 15% of the nominal value.
[0177] The inventors have further shown that treatment with DNase I prior to viral genome number determination results in a reduction in the determined viral copy genome number. This has been demonstrated using ATCC AAV2 standard VR-1616. The nominal viral genome copy number (vgcn) of the batch used in the experiment was 3.28*10E10 vg / mL. The results are shown in Table 5 below.
[0178] Table 5:
[0179]
[0180] The reduction caused by the DNase I treatment was independent of further processing of the samples, i.e., heat denaturation or proteinase K incubation. The different tested conditions, which all showed a defined reduction in viral copy number, are summarized in Table 6. The ATCC AAV2 standard VR-1616 has been used. The nominal viral genome copy number (vgcn) of the batch used in the experiments was 3.28*10E10 vg / mL.
[0181] Table 6:
[0182]
[0183]
[0184] The inventors' findings were confirmed using lysates from HEK293 cell cultures producing AAV2. The viral genome copy number (vgcn) determined in the lysate was 1.746*10E10 vg / mL (lysate 18). The results are shown in Table 7 below.
[0185] As can be seen, incubation with proteinase K allowed for a 96% recovery of viral genomes. The recovery could be further increased to 100% by incubating the samples with proteinase K in the presence of SDS.
[0186] Table 7:
[0187]
[0188] It must be noted that no further purification, i.e., for example, no column-based purification or extraction purification, was performed on the proteinase K incubated lysates.
[0189] The determined viral genome copy numbers after additional DNase I treatment were only in the range of 4% to 16%, as shown in Table 8 below.
[0190] Table 8:
[0191]
[0192] The inventors have found that for continuous incubations with DNA enzyme I and proteinase K, it is advantageous to use the entire incubation mixture of the DNA enzyme I incubation for the proteinase K incubation. The determined viral genome copy number can be increased to 80% of the established number. The established viral genome copy number (vgcn) in the lysate is 1.746*10E10 vg / mL (lysate 18) and 2.340*10E9 vg / mL (lysate 31). Such effects may not be seen in purified samples, such as ATCC standards (nominal viral genome copy number (vgcn) is 3.28*10E10 vg / mL). The results are shown in Table 9.
[0193] Table 9:
[0194]
[0195] The inventors have found that a combination of DNase I and proteinase K incubation can achieve a viral genome recovery of more than 80% without dilution of the cell lysate purified by affinity chromatography. The established viral genome copy number (vgcn) in the affinity purified lysate was 5.110*10E10 vg / mL (affinity purified lysate 31) and 7.320*10E10 vg / mL (affinity purified lysate 33). The results are shown in Table 10.
[0196] Table 10:
[0197]
[0198]
[0199] Viral genome quantification
[0200] To allow correct viral genome quantification, the sample must be free of plasmid DNA as well as unpackaged vector genomes, both of which contain at least partial viral genomes. In addition, packaged AAV genomes must be obtainable from the first PCR cycle.
[0201] To remove unpackaged DNA that could interfere with the ddPCR process, DNase I digestion is often used.
[0202] In order to make the encapsulated DNA accessible for ddPCR, the capsid needs to be opened. This can be accomplished by either high temperature incubation or proteinase K digestion. The need for proteinase K digestion has been much discussed in the art.
[0203] Droplet digital polymerase chain reaction
[0204] Droplet digital PCR (ddPCR) allows absolute quantification of viral genomes without the need to generate a standard curve.
[0205] In more detail, droplet digital polymerase chain reaction (ddPCR) achieves absolute quantification of nucleic acids by randomly distributing the PCR reaction mixture into discrete partitions, some of which have no nucleic acid target sequence and other partitions have one or more template copies (Hindson, B. et al., Anal. Chem. 83 (2011) 8604-8610). Due to the partitions, thousands of independent PCR reactions are performed during thermal cycling. At the end point, the score of the target positive partition is read out and used to calculate the initial template DNA concentration (Pinheiro, L. et al., Anal. Chem. 84 (2011) 1003-1011).
[0206] First, up to 20,000 droplets with a volume of about 1 nL are formed in a water-oil emulsion. Thus, the PCR reaction mixture is partitioned, and the PCR reaction mixture consists of a nucleic acid template, forward (fwd) and reverse (rev) primers, TaqMan probes, and a ddPCR supermix containing Thermus aquaticus (Taq) DNA polymerase, dNTPs, and PCR buffer (see, for example, Hindson, B. et al. 2011; Taylor, S et al., Sci. Rep. 7 (2017) 2409). During thermal cycling, a separate PCR reaction is performed in each droplet depending on the presence or absence of the DNA target.
[0207] In a droplet containing template DNA, the target sequence is amplified. During amplification, the 5' to 3' exonuclease activity of Taq polymerase hydrolyzes the TaqMan probe bound to the template chain. Because the probe is degraded into smaller fragments, the fluorophore at 5' is no longer close to its quencher at 3'. Thereby eliminating signal quenching and generating a fluorescent signal. The partition lacking the template sequence does not show amplification, and therefore there is no hydrolysis and fluorescence generation of the TaqMan probe, respectively, because the fluorescence of the fluorophore at 5' remains quenched (see, for example, Holland, P. et al., Proc. Natl. Acad. Sci. USA 88 (1991) 7276-7580). Since probes with different fluorophores can be used, these probes have different excitation and emission wavelengths, so ddPCR reactions can be performed as multiple reactions in one droplet. Commonly used fluorophores for two-dimensional ddPCR are 6-carboxyfluorescein (FAM) and hexachloro-6-carboxyfluorescein (HEX), both of which are quenched by black hole quencher 1 (BHQ1) (see, for example, Furuta-Hanawa, B. et al. Hum. Gen. Therap. Meth. 30 (2019) 127-136).
[0208] As an endpoint analysis, the fluorescence signal of each droplet after thermal cycling is read. The copy number (λ) of the target sequence can be calculated from the ratio of positive reads to total reads (p) according to Equation 1 using Poisson statistics (see, e.g., Hindson, B. et al. (2011)).
[0209] λ = - ln (1 – p) (1)
[0210] Since ddPCR relies on endpoint measurement, target sequence quantification is independent of PCR reaction efficiency to a certain extent. This is in contrast to real-time PCR (qPCR), which is commonly used for viral genome titration (see, e.g., Taylor, S et al. (2017)). In addition, no standards or calibration samples need to be used (see, e.g., Dorange, F., Bec, C., Cell Gen. Therap. Ins. 4 (2018) 119-129).
[0211] Recombinant AAV particles
[0212] Different methods for generating rAAV particles are known in the art. For example, transfection using AAV plasmids and AAV auxiliary sequences and co-infection with an AAV helper virus (e.g., adenovirus, herpes virus or vaccinia virus), or transfection using recombinant AAV plasmids, AAV helper plasmids and auxiliary function plasmids. Non-limiting methods for generating rAAV particles are described in, for example, US 6,001,650, US 6,004,797, WO 2017 / 096039 and WO 2018 / 226887. After recombinant rAAV particle production (i.e., particle generation in a cell culture system), rAAV particles can be obtained from host cells and cell culture supernatants and purified.
[0213] For the production of recombinant AAV particles, it is necessary to express the Rep and Cap proteins, the accessory proteins E1A, E1B, E2A and E4orf6, and the adenovirus VA RNA in a single mammalian cell. The accessory proteins E1A, E1B, E2A and E4orf6 can be expressed using any promoter, as shown by Matsushita et al. (Gene Ther. 5 (1998) 938-945), in particular the CMV IE promoter. Therefore, any promoter can be used.
[0214] In general, in order to produce recombinant AAV particles, different complementary plasmids are co-transfected into host cells. One of these plasmids contains a transgene sandwiched between two cis-acting AAV ITRs. The deleted AAV elements (i.e., open reading frames for Rep and Cap proteins) required for offspring recombinant genome replication and subsequent packaging are contained in the second plasmid in trans. Overexpression of Rep protein causes an inhibitory effect on cell growth (Li, J. et al., J. Virol. 71 (1997) 5236-5243). In addition, AAV replication requires a third plasmid containing genes of helper viruses (i.e., E1, E4orf6, E2A and VA from adenovirus).
[0215] To reduce the number of plasmids required, Rep, Cap, and adenoviral helper genes can be combined on a single plasmid.
[0216] Alternatively, the host cell may have stably expressed the E1 gene product. Such cells are HEK293 cells. The human embryonic kidney clone, denoted 293, was generated as early as 1977 by integrating adenovirus DNA into human embryonic kidney cells (HEK cells) (Graham, FL et al., J. Gen. Virol. 36 (1977) 59-74). The HEK293 cell line contains base pairs 1 to 4344 of the adenovirus serotype 5 genome. This covers E1A and E1B genes and adenovirus packaging signals (Louis, N. et al., Virology 233 (1997) 423-429).
[0217] When HEK293 cells are used, the deleted E2A, E4orf6 and VA genes can be introduced by co-infection with adenovirus or by co-transfection with plasmids expressing E2A, E4orf6 and VA (see, e.g., Samulski, RJ et al., J. Virol. 63 (1989) 3822-3828; Allen, JM et al., J. Virol. 71 (1997) 6816-6822; Tamayose, K. et al., Hum. Gene Ther. 7 (1996) 507-513; Flotte, TR et al., Gene Ther. 2 (1995) 29-37; Conway, JE et al., J. Virol. 71 (1997) 8780-8789; Chiorini, JA et al., Hum. Gene Ther. 6 (1995) 1531-1541; Ferrari, FK et al., J. Virol. 70 (1996) 3227-3234; Salvetti, A. et al., Hum. Gene Ther. 9 (1998) 695-706; Xiao, X. et al., J. Virol. 72 (1998) 2224-2232; Grimm, D. et al., Hum. Gene Ther. 9 (1998) 2745-2760; Zhang, X. et al., Hum. Gene Ther. 10 (1999) 2527-2537). Alternatively, adenovirus / AAV or herpes simplex virus / AAV hybrid vectors may be used (see, e.g., Conway, JE et al., J. Virol. 71 (1997) 8780-8789; Johnston, KM et al., Hum. Gene Ther. 8 (1997) 359-370; Thrasher, AJ et al., Gene Ther. 2 (1995) 481-485; Fisher, JK et al., Hum. Gene Ther. 7 (1996) 2079-2087; Johnston, KM et al., Hum. Gene Ther. 8 (1997) 359-370).
[0218] Therefore, cell lines in which the rep gene is integrated and expressed tend to grow slowly or express the Rep protein at very low levels.
[0219] To restrict transgene activity to specific tissues, ie, to limit integration sites, the transgene can be operably linked to an inducible or tissue-specific promoter (see, eg, Yang, Y. et al. Hum. Gene. Ther. 6 (1995) 1203-1213).
[0220] One difficulty in rAAV particle production is the inefficiency of rAAV vector packaging, resulting in low titers. Packaging has been difficult for a number of reasons, including:
[0221] - Preferred encapsidation of the wild-type AAV genome when present;
[0222] - Due to the repression associated with the rep gene product, it is difficult to generate adequate complementary functions, such as those provided by wild-type rep and cap genes;
[0223] - The efficiency of co-transfection of plasmid constructs is limited.
[0224] All of this is based on the biological properties of the Rep protein. In particular, the inhibitory (cytostatic and cytotoxic) properties of the Rep protein and its ability to reverse the immortalized phenotype of cultured cells are problematic. In addition, when the widely used AAV P5 promoter is adopted, the Rep proteins downregulate their own expression (see, for example, Tratschin et al., Mol. Cell. Biol. 6 (1986) 2884-2894).
[0225] In certain embodiments of all aspects and embodiments, the rAAV particles are derived from an AAV selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, Rh.10, Rh74 and 7m8.
[0226] In certain embodiments of all aspects and embodiments, the rAAV particle comprises a capsid sequence having 70% or greater sequence identity to an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, Rh.10, Rh74, or 7m8 capsid sequence.
[0227] In certain embodiments of all aspects and embodiments, the rAAV particle comprises an ITR sequence having 70% or greater sequence identity to an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, or AAV10 ITR sequence.
[0228] E1A, E1B, E2 and E4
[0229] The coding sequences (open reading frames) of E1A and E1B may be derived from human adenoviruses, such as, for example, in particular human adenovirus serotype 2 or serotype 5. Exemplary sequences of human Ad5 (adenovirus serotype 5) are found in GenBank entries X02996, AC_000008, and the sequence of an exemplary human Ad2 is found in GenBank entry AC_000007. Nucleotides 505 to 3522 comprise the nucleic acid sequence encoding E1A and E1B of human adenovirus serotype 5. Plasmid pSTK146 reported in EP 1 230 354 and plasmids pGS119 and pGS122 reported in WO2007 / 056994 may also be used as sources of E1A and E1B open reading frames.
[0230] E1A is the first viral helper gene expressed after adenoviral DNA enters the cell nucleus. The E1A gene encodes 12S and 13S proteins, which are based on the same E1A mRNA by alternative splicing. The expression of 12S and 13S proteins causes the activation of other viral functions E1B, E2, E3 and E4. In addition, the expression of 12S and 13S proteins forces the cell to enter the S phase of the cell cycle. If only E1A-derived proteins are expressed, the cell will die (apoptosis).
[0231] E1B is the second viral helper gene expressed. It is activated by E1A-derived proteins 12S and 13S. The mRNA derived from the E1B gene can be spliced in two different ways, resulting in a first 55kDa transcript and a second 19kDa transcript. The E1B 55kDa protein is involved in regulating the cell cycle, blocking mRNA trafficking in late infected cells, and preventing E1A-induced apoptosis. The E1B 19kDa protein is involved in preventing E1A-induced apoptosis.
[0232] The E2 genes encode different proteins. The E2A transcript encodes the single-stranded binding protein (SSBP), which is essential for AAV replication.
[0233] The E4 gene also encodes multiple proteins. The 34kDa protein (E4orf6) derived from the E4 gene, together with the E1B 55kDa protein, prevents the accumulation of cellular mRNA in the cytoplasm, but also promotes the transport of viral RNA from the nucleus to the cytoplasm.
[0234] Adenovirus VA RNA gene
[0235] Virus-associated RNA (VA RNA) is a non-coding RNA of adenovirus (Ad) that regulates translation. The adenovirus genome contains two independent copies: VAI (VA RNAI) and VAII (VA RNAII). Both are transcribed from a type 2 polymerase III promoter by RNA polymerase III (see, e.g., Machitani, M. et al., J. Contr. Rel. 154 (2011) 285-289). For recombinant production, the adenovirus VA RNA gene can be driven by any promoter.
[0236] Ma, Y. and Mathews, MB (J. Virol. 70 (1996) 5083-5099) used a phylogenetic approach to study the structure, function and evolution of adenovirus-associated RNA. They provided an alignment based on 47 known human adenovirus serotypes and a consensus VA RNA sequence. The disclosure is hereby incorporated by reference into this application in its entirety.
[0237] VA RNA, VAI and VAII consist of 157 to 160 nucleotides (nt).
[0238] Depending on the serotype, adenovirus contains one or two VA RNA genes. VA RNAI is thought to play a major proviral role, while VA RNAII can partially compensate for the absence of VA RNAI (Vachon, VK and Conn, GL, Virus Res. 212 (2016) 39-52).
[0239] VA RNA is not essential, but plays an important role in efficient viral growth by overcoming cellular antiviral mechanisms. That is, although VA RNA is not essential for viral growth, adenoviruses lacking VA RNA fail to grow during the initial steps of vector generation, where only a few copies of the viral genome are present per cell, probably because viral genes other than VARNA that block cellular antiviral mechanisms may not be adequately expressed (see Maekawa, A. et al. Nature Sci. Rep. 3 (2013) 1136).
[0240] Maekawa, A. et al. (Nature Sci. Rep. 3 (2013) 1136) reported the efficient production of adenoviral vectors lacking genes for virus-associated RNAs that disrupt the cellular RNAi machinery, in which HEK293 cells that constitutively and highly express flippase recombinase were infected to obtain VA RNA-deficient adenoviruses through FLP recombinase-mediated excision of the VA RNA locus.
[0241] Human adenovirus 2VA RNAI corresponds to nucleotides 10586-10810 of the sequence of GenBank entry AC_000007. Human adenovirus 5VA RNAI corresponds to nucleotides 10579-10820 of the sequence of GenBank entry AC_000008.
[0242] Methods for producing rAAV particles
[0243] Carter et al. have shown that the entire rep and cap open reading frames in the wild-type AAV genome can be deleted and replaced with transgenes (Carter, BJ, "Handbook of Parvoviruses", P. Tijssen ed., CRC Press, pp. 155-168 (1990)). In addition, it is reported that ITRs must be maintained to retain the functions of transgene replication, rescue, packaging and integration into the target cell genome.
[0244] When cells containing the corresponding viral helper genes are transduced with AAV vectors, or vice versa, when cells containing integrated AAV provirus are transduced with appropriate helper virus, the AAV provirus is activated and enters the lytic infection cycle again (Clark, KR et al., Hum. Gene Ther. 6 (1995) 1329-1341; Samulski, RJ, Curr. Opin. Genet. Dev. 3 (1993) 74-80).
[0245] Aspects of the invention are methods of transducing cells with a nucleic acid (e.g., a plasmid) comprising all the required elements for producing recombinant AAV particles, wherein the viral genome copy number is determined using a method according to the invention. Thus, when the plasmid encodes viral packaging proteins and / or accessory proteins, the cell can produce recombinant viral particles comprising a nucleic acid encoding a protein of interest or a nucleic acid comprising a sequence that is transcribed into a transcript of interest.
[0246] The present invention provides a viral (eg, AAV) particle production platform that includes features that distinguish it from current 'industry standard' viral (eg, AAV) particle production processes through the use of methods according to the present invention.
[0247] More generally, cells transfected or transduced with DNA for recombinant production of AAV particles can be referred to as "recombinant cells". Such cells can be, for example, yeast cells, insect cells or mammalian cells, and have been used as receptors for nucleic acids (plasmids) encoding packaging proteins (such as AAV packaging proteins), nucleic acids (plasmids) encoding auxiliary proteins, and nucleic acids (plasmids) encoding proteins or transcribed into target transcripts (i.e., transgenes placed between two AAV ITRs). The term includes the descendants of the original cells that have been transduced or transfected. It should be understood that the descendants of a single parental cell may not necessarily be exactly the same as the original parent in terms of morphology or genome or total nucleic acid complement due to natural, accidental or deliberate mutations.
[0248] Many cell growth mediums suitable for maintaining cell viability or providing cell growth and / or proliferation are commercially available. The example of such culture medium includes serum-free eukaryotic growth medium, such as for maintaining mammalian (e.g., human) cell viability or providing mammalian (e.g., human) cell growth medium. Non-limiting examples include Ham's F12 or F12K culture medium (Sigma-Aldrich), FreeStyle (FS) F17 culture medium (Thermo-Fisher Scientific), MEM, DMEM, RPMI-1640 (Thermo-Fisher Scientific) and mixtures thereof. Such culture medium can be supplemented with vitamins and / or trace minerals and / or salts and / or amino acids, such as essential amino acids for mammalian (e.g., human) cells.
[0249] The helper protein plasmid can be in the form of a plasmid, phage, transposon or cosmid. In particular, it has been shown that helper function does not require a complete complement of adenoviral genes. For example, adenoviral mutants that are unable to carry out DNA replication and late gene synthesis have been shown to allow AAV replication. Ito et al., J. Gen. Virol. 9 (1970) 243; Ishibashi et al., Virology 45 (1971) 317.
[0250] Mutants within the E2B and E3 regions have been shown to support AAV replication, indicating that the E2B and E3 regions may not be involved in providing auxiliary functions. Carter et al., Virology 126 (1983) 505. However, adenoviruses with defects in the E1 region or deletions in the E4 region cannot support AAV replication. Therefore, for adenovirus auxiliary proteins, the E1A and E4 regions may be directly or indirectly required for AAV replication (see, e.g., Laughlin et al., J. Virol. 41 (1982) 868; Janik et al., Proc. Natl. Acad. Sci. USA 78 (1981) 1925; Carter et al., Virology 126 (1983) 505). Other characterized adenovirus mutants include: E1B (Laughlin et al. (1982), supra; Janik et al. (1981), supra; Ostrove et al., Virology 104 (1980) 502); E2A (Handa et al., J. Gen. Virol. 29 (1975) 239; Strauss et al., J. Virol. 17 (1976) 140; Myers et al., J. Virol. 35 (1980) 665; Jay et al., Proc. Natl. Acad. Sci. USA 78 (1981) 2927; Myers et al., J. Biol. Chem. 256 (1981) 567); E2B (Carter, Adeno-Associated Virus Helper Functions, I CRC Handbook of Parvoviruses (P. Tijssen, ed., 1990)); E3 (Carter et al. (1983), supra); and E4 (Carter et al. (1983), supra; Carter (1995)).
[0251] Studies on helper proteins provided by adenoviruses with E1B mutations have reported that the E1B 55 kDa protein is essential for AAV particle production, whereas the E1B 19 kDa is not. In addition, WO 97 / 17458 and Matshushita et al. (Gene Therapy 5 (1998) 938-945) describe helper plasmids encoding various adenovirus genes. Examples of helper plasmids include adenovirus VA RNA coding regions, adenovirus E4orf6 coding regions, adenovirus E2A 72 kDa coding regions, adenovirus E1A coding regions, and adenovirus E1B regions lacking the complete E1B 55 kDa coding region (see, e.g., WO 01 / 83797).
[0252] Therefore, the present invention provides a method for producing a recombinant AAV vector or an AAV particle comprising the recombinant AAV vector using the method for viral genome number determination according to the present invention, wherein the recombinant AAV vector comprises a nucleic acid encoding a protein or transcribed into a target transcript.
[0253] One aspect of the present invention is a method for producing a recombinant AAV vector or an AAV particle comprising the recombinant AAV vector, wherein the recombinant AAV vector comprises a nucleic acid encoding a protein or transcribed into a target transcript, the method comprising the following steps:
[0254] (i) providing one or more plasmids comprising nucleic acids encoding AAV packaging proteins and / or nucleic acids encoding accessory proteins;
[0255] (ii) providing a plasmid comprising a nucleic acid encoding a target protein or transcribed into a target transcript;
[0256] (iii) contacting one or more mammalian or insect cells with a provided plasmid;
[0257] (iv) further adding a transfection reagent and optionally incubating the plasmid / transfection reagent / cell mixture;
[0258] or providing physical means, such as an electric current, to introduce the nucleic acid into the cell;
[0259] (v) culturing the transfected cells;
[0260] (vi) harvesting the cultured cells and / or medium from the cultured cells to produce a cell and / or medium harvest; and
[0261] (vii) lysing the cells and optionally isolating the recombinant AAV vector or AAV particles from the cells and / or culture medium harvest lysate;
[0262] (viii) determining the viral genome copy number in or after step (vi) or / and step (vii) using the method according to the present invention;
[0263] Thereby, a recombinant AAV vector or AAV particle comprising a nucleic acid encoding a protein of interest or transcribed into a transcript of interest is produced.
[0264] One aspect of the present invention is a method for producing a recombinant AAV vector or an AAV particle comprising the recombinant AAV vector, wherein the recombinant AAV vector comprises a nucleic acid encoding a protein or transcribed into a target transcript, the method comprising the following steps:
[0265] (i) providing one or more plasmids comprising nucleic acids encoding AAV packaging proteins and / or nucleic acids encoding accessory proteins;
[0266] (ii) providing a plasmid comprising a nucleic acid encoding a target protein or transcribed into a target transcript;
[0267] (iii)
[0268] (a) Generate stably transfected cells by
[0269] - contacting one or more mammalian or insect cells with the provided plasmid of (i);
[0270] - further adding a transfection reagent and optionally incubating the plasmid / transfection reagent / cell mixture; or providing physical means, such as an electric current, to introduce the nucleic acid into the cells;
[0271] - selecting a first stably transfected cell;
[0272] - contacting the selected first stably transfected cells with the provided plasmid of (ii); and
[0273] - further adding a transfection reagent and optionally incubating the plasmid / transfection reagent / cell mixture; or providing physical means, such as an electric current, to introduce the nucleic acid into the cells;
[0274] (b) or generate transiently transfected cells by
[0275] - contacting one or more mammalian or insect cells with the provided plasmids of (i) and (ii); and
[0276] - further adding a transfection reagent and optionally incubating the plasmid / transfection reagent / cell mixture; or providing physical means, such as an electric current, to introduce the nucleic acid into the cells;
[0277] (iv) culturing the transfected cells of (iii);
[0278] (v) harvesting the cultured cells and / or medium from the cultured cells to produce a cell and / or medium harvest;
[0279] (vi) lysing the cells and optionally isolating the recombinant AAV vector or AAV particles from the cells and / or culture medium harvest lysate;
[0280] (vii) determining the viral genome copy number in or after step (v) or / and step (vi) using the method according to the present invention;
[0281] Thereby, a recombinant AAV vector or AAV particle comprising a nucleic acid encoding a protein of interest or transcribed into a transcript of interest is produced.
[0282] One aspect of the present invention is a method for producing a recombinant AAV vector or an AAV particle comprising the recombinant AAV vector, wherein the recombinant AAV vector comprises a nucleic acid encoding a protein or transcribed into a target transcript, the method comprising the following steps:
[0283] (i) providing a mammalian or insect cell comprising a nucleic acid encoding an AAV packaging protein and / or a nucleic acid encoding an accessory protein;
[0284] (ii) providing a plasmid comprising a nucleic acid encoding a target protein or transcribed into a target transcript;
[0285] (iii)
[0286] (a) Generate stably transfected cells by
[0287] - contacting one or more mammalian or insect cells with the provided plasmid of (i);
[0288] - further adding a transfection reagent and optionally incubating the plasmid / transfection reagent / cell mixture; or providing physical means, such as an electric current, to introduce the nucleic acid into the cells;
[0289] - selecting a first stably transfected cell;
[0290] - contacting the selected first stably transfected cells with the provided plasmid of (ii); and
[0291] - further adding a transfection reagent and optionally incubating the plasmid / transfection reagent / cell mixture; or providing physical means, such as an electric current, to introduce the nucleic acid into the cells;
[0292] (b) or generate transiently transfected cells by
[0293] - contacting one or more mammalian or insect cells with the provided plasmids of (i) and (ii); and
[0294] - further adding a transfection reagent and optionally incubating the plasmid / transfection reagent / cell mixture; or providing physical means, such as an electric current, to introduce the nucleic acid into the cells;
[0295] (iv) culturing the transfected cells of (iii);
[0296] (v) harvesting the cultured cells and / or medium from the cultured cells to produce a cell and / or medium harvest;
[0297] (vi) lysing the cells and optionally isolating and / or purifying the recombinant AAV vector or AAV particles from the cells and / or culture medium harvest; and
[0298] (vii) determining the viral genome copy number in or after step (v) or / and step (vi) using the method according to the present invention;
[0299] Thereby, a recombinant AAV vector or AAV particle comprising a nucleic acid encoding a protein of interest or transcribed into a transcript of interest is produced.
[0300] Introduction of nucleic acids (plasmids) into cells can be done in a variety of ways.
[0301] The various methods of transferring DNA to mammalian cells have been reported in the art. These can be used according to the method of the present invention. In certain embodiments of all aspects and embodiments, electroporation, nuclear transfection or microinjection for nucleic acid transfer / transfection is used. In certain embodiments of all aspects and embodiments, inorganic substances (such as calcium phosphate / DNA coprecipitation), cationic polymers (such as polyethyleneimine, DEAE-dextran) or cationic lipids (lipofection) for nucleic acid transfer / transfection are used. Calcium phosphate and polyethyleneimine are the most commonly used reagents in the transfection for larger-scale nucleic acid transfer (see, for example, Baldi et al., Biotechnol.Lett.29 (2007) 677-684), wherein polyethyleneimine is preferred.
[0302] In certain embodiments of all aspects and embodiments, nucleic acid (plasmid) is provided in the form of a composition in combination with polyethyleneimine (PEI), optionally in combination with cells. In certain embodiments, the composition includes a plasmid / PEI mixture having multiple components: (a) one or more plasmids comprising nucleic acids encoding AAV packaging proteins and / or nucleic acids encoding auxiliary proteins; (b) a plasmid comprising a nucleic acid encoding a protein or transcribed into a target transcript; and (c) a polyethyleneimine (PEI) solution. In certain embodiments, the molar ratio of the plasmid ranges from about 1:0.01 to about 1:100, or a molar ratio ranges from about 100:1 to about 1:0.01, and the mixture of components (a), (b) and (c) is optionally incubated for a period of about 10 seconds to about 4 hours.
[0303] In certain embodiments of all aspects and embodiments, the composition further comprises a cell. In certain embodiments, the cell is contacted with the plasmid / PEI mixture of components (a), (b) and / or (c).
[0304] In certain embodiments of all aspects and embodiments, the composition optionally combined with the cells further comprises free PEI. In certain embodiments, the cells are contacted with free PEI.
[0305] In certain embodiments of all aspects and embodiments, the cell has been contacted with a mixture of components (a), (b) and / or (c) for at least about 4 hours, or from about 4 hours to about 140 hours, or from about 4 hours to about 96 hours. In a preferred embodiment, the cell has been contacted with a mixture of components (a), (b) and / or (c) and optionally free PEI for at least about 4 hours.
[0306] Said composition can further comprise plasmid or / and cell.Such plasmid and cell can contact with free PEI.In certain embodiments, plasmid and / or cell have contacted with free PEI at least about 4 hours, or about 4 hours to about 140 hours, or about 4 hours to about 96 hours.
[0307] The present invention also provides a method for producing transfected cells. The method includes providing one or more plasmids; providing a solution comprising polyethyleneimine (PEI); and mixing the plasmid with the PEI solution to produce a plasmid / PEI mixture. In certain embodiments, such a mixture is incubated for a period of about 10 seconds to about 4 hours. In such methods, the cells are then contacted with the plasmid / PEI mixture to produce a plasmid / PEI cell culture; free PEI is then added to the produced plasmid / PEI cell culture to produce free PEI / plasmid / PEI cell culture; the produced free PEI / plasmid / PEI cell culture is then incubated for at least about 4 hours, thereby producing transfected cells. In certain embodiments, the plasmid comprises one or more or all of a rep open reading frame, a cap open reading frame, an E1A, E1B, E2 and an E4orf6 open reading frame, and a nucleic acid encoding a protein or transcribed into a target transcript.
[0308] Further provided is a method for producing a transfected cell that produces a recombinant AAV vector or AAV particle, the method comprising providing one or more plasmids comprising a nucleic acid encoding an AAV packaging protein and / or a nucleic acid encoding an auxiliary protein; providing a plasmid comprising a nucleic acid encoding a protein or transcribed into a target transcript; providing a solution comprising polyethyleneimine (PEI); mixing the above plasmids with the PEI solution, wherein the molar ratio of the plasmids ranges from about 1:0.01 to about 1:100, or the molar ratio ranges from about 100:1 to about 1:0.01, to produce a plasmid / PEI mixture (and any Preferably, the plasmid / PEI mixture is incubated for a period ranging from about 10 seconds to about 4 hours); contacting the cells with the plasmid / PEI mixture to produce a plasmid / PEI cell culture; adding free PEI to the produced plasmid / PEI cell culture to produce a free PEI / plasmid / PEI cell culture; and incubating the free PEI / plasmid / PEI cell culture for at least about 4 hours, thereby producing transfected cells that produce recombinant AAV vectors or particles comprising nucleic acids encoding proteins or transcribed into target transcripts, wherein the viral genome copy number is determined using the method according to the present invention.
[0309] Also provided is a method for producing a recombinant AAV vector or AAV particle comprising a nucleic acid encoding a protein or transcribed into a target transcript, the method comprising providing one or more plasmids comprising a nucleic acid encoding an AAV packaging protein and / or a nucleic acid encoding an auxiliary protein; providing a plasmid comprising a nucleic acid encoding a target protein or transcribed into a target transcript; providing a solution comprising polyethyleneimine (PEI); mixing the above plasmids with the PEI solution, wherein the molar ratio of the plasmids ranges from about 1:0.01 to about 1:100, or the molar ratio ranges from about 100:1 to about 1:0.01, to produce a plasmid / PEI mixture (and optionally incubating the plasmid / PEI mixture for a period of time ranging from about 10 seconds to about 4 hours); mixing cells with the plasmid / PEI solution produced as described above The invention relates to a method of producing a plasmid / PEI cell culture comprising: contacting the produced plasmid / PEI cell culture with a culture medium to produce a plasmid / PEI cell culture; adding free PEI to the plasmid / PEI cell culture produced as described above to produce a free PEI / plasmid / PEI cell culture; incubating the produced plasmid / PEI cell culture or the free PEI / plasmid / PEI cell culture for at least about 4 hours to produce transfected cells; harvesting the produced transfected cells and / or the culture medium from the produced transfected cells to produce a cell and / or culture medium harvest; lysing the cells and optionally isolating the recombinant AAV vector or particle from the cell and / or culture medium harvest lysate, thereby determining the number of viral genome copies in the lysate or the isolated AAV particle using a method according to the invention; thereby producing a recombinant AAV vector or particle comprising a nucleic acid encoding a protein or transcribed into a target transcript.
[0310] Methods for producing recombinant AAV vectors or AAV particles using methods according to the invention may include one or more additional steps or features. Exemplary steps or features include, but are not limited to, steps of harvesting produced cultured cells and / or harvesting culture medium from produced cultured cells to produce cell and / or culture medium harvests. Additional exemplary steps or features include, but are not limited to, lysing harvested cells and optionally isolating recombinant AAV vectors or AAV particles from cell and / or culture medium harvest lysates; wherein the viral genome copy number is determined using methods according to the invention; thereby producing recombinant AAV vectors or AAV particles comprising nucleic acids encoding proteins or transcribed into target transcripts.
[0311] In certain embodiments of all aspects and embodiments, PEI is added to plasmid and / or cells at different time points. In certain embodiments, free PEI is added to cells before, simultaneously with or after contacting the plasmid / PEI mixture with cells.
[0312] In some embodiments of all aspects and embodiments, when contacting with plasmid / PEI mixture and / or when contacting with free PEI, cell is in specific density and / or cell growth phase and / or vigor.In a preferred embodiment, when contacting with plasmid / PEI mixture and / or when contacting with free PEI, the density of cell is in the range of about 1x10E5 individual cells / mL to about 1x10E8 individual cells / mL.In certain embodiments, when contacting with plasmid / PEI mixture or with free PEI, cell viability is about 60% or greater than 60%, or wherein when contacting with plasmid / PEI mixture, cell is in logarithmic growth phase, or when contacting with plasmid / PEI mixture or with free PEI, cell viability is about 90% or greater than 90%, or wherein when contacting with plasmid / PEI mixture or with free PEI, cell is in logarithmic growth phase.
[0313] In certain embodiments of all aspects and embodiments, the encoded AAV packaging proteins include AAV rep and / or AAV cap. In certain embodiments of all aspects and embodiments, such AAV packaging proteins include AAV rep and / or AAV cap proteins of any AAV serotype.
[0314] In certain embodiments of all aspects and embodiments, the encoded accessory proteins include adenoviral E1A and E1B, adenoviral E2 and / or E4, VA RNA and / or non-AAV accessory proteins.
[0315] In certain embodiments of all aspects and embodiments, nucleic acids (plasmids) are used in specific amounts or ratios. In certain embodiments, the total amount of a plasmid comprising a nucleic acid encoding a protein or transcribed into a target transcript and one or more plasmids comprising a nucleic acid encoding an AAV packaging protein and / or a nucleic acid encoding an auxiliary protein is in the range of about 0.1 μg to about 15 μg per mL of cells. In certain embodiments, the molar ratio of a plasmid comprising a nucleic acid encoding a protein or transcribed into a target transcript to one or more plasmids comprising a nucleic acid encoding an AAV packaging protein and / or a nucleic acid encoding an auxiliary protein is in the range of about 1:5 to about 1:1, or in the range of about 1:1 to about 5:1.
[0316] In certain embodiments of all aspects and embodiments, the first plasmid comprises a nucleic acid encoding an AAV packaging protein and the second plasmid comprises a nucleic acid encoding an accessory protein.
[0317] In certain embodiments of all aspects and embodiments, the molar ratio of the plasmid comprising a nucleic acid encoding a protein or transcribed into a target transcript to the first plasmid comprising a nucleic acid encoding an AAV packaging protein to the second plasmid comprising a nucleic acid encoding an auxiliary protein in the co-transfection is in the range of about 1-5:1:1 or 1:1-5:1 or 1:1:1-5.
[0318] In certain embodiments of all aspects and embodiments, the cell is a eukaryotic cell. In certain embodiments, the eukaryotic cell is a mammalian cell. In a preferred embodiment, the cell is a HEK293 cell or a CHO cell.
[0319] The usual conditions for culturing eukaryotic cells at about 37° C., 95% humidity and 8% CO2 by volume can be used for culturing. Cultivation can be carried out in serum-containing or serum-free medium, adherent culture or suspension culture. Suspension culture can be carried out in any fermentation vessel, such as, for example, in a stirred tank reactor, a wave reactor, a rocking bioreactor, a shaking container or a rotating container or a so-called roller bottle. Transfection can be carried out in a high-throughput format and screening, for example, in a 96 or 384-well format, respectively.
[0320] The methods according to the invention include AAV particles of any serotype or variants thereof. In certain embodiments of all aspects and embodiments, the recombinant AAV particles comprise any one of the following: AAV serotypes 1 to 12, AAV VP1, VP2 and / or VP3 capsid proteins, or modified or variant AAV VP1, VP2 and / or VP3 capsid proteins, or wild-type AAV VP1, VP2 and / or VP3 capsid proteins. In certain embodiments of all aspects and embodiments, the AAV particles comprise an AAV serotype or an AAV pseudotype, wherein the AAV pseudotype comprises an AAV capsid serotype different from the ITR serotype.
[0321] The methods according to the invention that provide or include AAV vectors or particles may also include other elements. Examples of such elements include, but are not limited to, introns, expression control elements, one or more adeno-associated virus (AAV) inverted terminal repeats (ITRs) and / or filler / filler polynucleotide sequences. Such elements may be located within or flanking a nucleic acid encoding a protein or transcribed into a target transcript, or an expression control element may be operably linked to a nucleic acid encoding a protein or transcribed into a target transcript, or an AAV ITR may flank the 5' or 3' end of a nucleic acid encoding a protein or transcribed into a target transcript, or a filler polynucleotide sequence may flank the 5' or 3' end of a nucleic acid encoding a protein or transcribed into a target transcript.
[0322] Expression control elements include constitutive or regulatable control elements, such as tissue-specific expression control elements or promoters.
[0323] The ITR may be any of AAV2 or AAV6 or AAV8 or AAV9 serotypes, or a combination thereof. The AAV particles may include any VP1, VP2 and / or VP3 capsid proteins having 75% or greater sequence identity with any of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV10, AAV11, AAV-2i8, AAV rh74 or AAV 7m8 VP1, VP2 and / or VP3 capsid proteins, or a modified or variant VP1, VP2 and / or VP3 capsid protein selected from any of the following: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV10, AAV11, AAV-2i8, AAV rh74 and AAV 7m8 AAV serotypes.
[0324] After producing recombinant virus (e.g., AAV) particles as described herein, if desired, a variety of conventional methods can be used to purify and / or separate virus (e.g., rAAV) particles from host cells. Such methods include column chromatography, CsCl gradients, iodixanol gradients, etc.
[0325] For example, multiple column purification steps can be used, such as purification by anion exchange column, affinity column and / or cation exchange column. (See, for example, WO 02 / 12455 and US 2003 / 0207439). Alternatively or in addition, iodixanol or CsCl gradient steps can be used (see, for example, US2012 / 0135515; and US2013 / 0072548). In addition, if infectious viruses are used to express packaging proteins and / or auxiliary proteins, various methods can be used to inactivate residual viruses. For example, adenovirus can be inactivated by heating to a temperature of about 60° C. for, for example, 20 minutes or longer. This treatment effectively inactivates the helper virus because AAV is heat stable, while the helper adenovirus is heat unstable.
[0326] One goal of rAAV vector production and purification systems is to implement strategies to minimize / control the generation of production-related impurities, such as proteins, nucleic acids, and vector-related impurities, including wild-type / pseudo-wild-type AAV species (wtAAV) and residual DNA impurities encapsulated by AAV.
[0327] Considering that rAAV particles account for only a small part of the biomass, rAAV particles need to be purified to a purity level that can be used as a clinical human gene therapy product (see, for example, Smith PH et al., Mo. Therapy 7 (2003) 8348; Chadeuf G. et al., Mo. Therapy 12 (2005) 744; report from the CHMP gene therapy expert group meeting, European Medicines Agency EMEA / CHMP 2005, 183989 / 2004).
[0328] As an initial step, cultured cells producing rAAV particles are typically harvested and optionally combined with harvested cell culture supernatant (culture medium) in which cells (suspension cells or adherent cells) producing rAAV particles have been cultured. The harvested cells and optional cell culture supernatant can be used as is, lysed or concentrated as appropriate. In addition, if infection is used to express auxiliary functions, residual helper viruses can be inactivated. For example, adenoviruses can be inactivated by heating to a temperature of about 60° C. for, for example, 20 minutes or longer, which only inactivates the helper virus because AAV is heat stable, while helper adenoviruses are heat unstable.
[0329] The supernatant of the cells and / or harvest is lysed by destroying the cells (e.g., by chemical or physical means, such as detergents, microfluidization and / or homogenization) to release rAAV particles. During cell lysis or subsequently after cell lysis, a nuclease (such as, for example, benzonase) is added to degrade contaminated DNA. Typically, the resulting lysate is clarified to remove cell debris, for example, by filtering or centrifugation to obtain a clarified cell lysate. In a specific example, the lysate is filtered with a micron diameter pore size filter (such as a 0.1 μm to 10.0 μm pore size filter, for example, a 0.45 μm and / or pore size 0.2 μm filter) to produce a clarified lysate.
[0330] The lysate (optionally clarified) contains AAV particles (including rAAV vectors as well as empty capsids) and production / process-related impurities, such as soluble cellular components from host cells, which may include cell proteins, lipids and / or nucleic acids, and cell culture medium components, among others. The optionally clarified lysate is then subjected to a purification step to purify the AAV particles (including rAAV vectors) from the impurities using chromatography. Prior to the first chromatography step, the clarified lysate may be diluted or concentrated with an appropriate buffer.
[0331] Following cell lysis, optional clarification, and optional dilution or concentration, multiple subsequent and sequential chromatography steps may be used to purify the rAAV particles.
[0332] The first chromatography step can be cation exchange chromatography or anion exchange chromatography. If the first chromatography step is cation exchange chromatography, the second chromatography step can be anion exchange chromatography or size exclusion chromatography (SEC). Therefore, in certain embodiments of all aspects and embodiments, the rAAV particle purification is a purification via cation exchange chromatography followed by a purification via anion exchange chromatography.
[0333] Alternatively, if the first chromatography step is cation exchange chromatography, the second chromatography step can be size exclusion chromatography (SEC). Thus, in certain embodiments of all aspects and embodiments, the rAAV particle purification is purification via cation exchange chromatography followed by purification via size exclusion chromatography (SEC).
[0334] Still alternatively, the first chromatography step can be affinity chromatography. If the first chromatography step is affinity chromatography, the second chromatography step can be anion exchange chromatography. Thus, in certain embodiments of all aspects and embodiments, the rAAV particle purification is purification via affinity chromatography followed by purification via anion exchange chromatography.
[0335] Optionally, a third chromatography may be added to the preceding chromatography steps. Typically, the optional third chromatography step follows cation exchange, anion exchange, size exclusion or affinity chromatography.
[0336] Thus, in certain embodiments of all aspects and embodiments, rAAV particle purification is purification via cation exchange chromatography, followed by purification via anion exchange chromatography, followed by purification via size exclusion chromatography (SEC).
[0337] Furthermore, in certain embodiments of all aspects and embodiments, the further rAAV particle purification is purification via cation exchange chromatography, followed by purification via size exclusion chromatography (SEC), followed by purification via anion exchange chromatography.
[0338] In yet further embodiments of all aspects and embodiments, the rAAV particle purification is purification via affinity chromatography followed by purification via anion exchange chromatography followed by purification via size exclusion chromatography (SEC).
[0339] In yet further embodiments of all aspects and embodiments, the rAAV particle purification is purification via affinity chromatography followed by purification via size exclusion chromatography (SEC) followed by purification via anion exchange chromatography.
[0340] The role of cation exchange chromatography is to separate AAV particles from cells and other components present in the clarified lysate and / or column eluate from affinity chromatography or size exclusion chromatography. Examples of strong cation exchange resins capable of binding rAAV particles over a wide pH range include, but are not limited to, any sulfonic acid-based resin indicated by the presence of a sulfonate functional group, including aryl and alkyl substituted sulfonates, such as sulfopropyl or sulfoethyl resins. Representative matrices include, but are not limited to, POROS HS, POROS HS 50, POROS XS, POROS SP, and POROS S (strong cation exchangers available from ThermoFisher Scientific, Inc., Waltham, MA, USA). Additional examples include Capto S, Capto SImpAct, Capto S ImpRes (strong cation exchangers available from GE Healthcare, Marlborough, MA, USA), and commercial preparations of resins available from Aldrich Chemical Company (Milliwaukee, WI, USA). and Family. Weak cation exchange resins include, but are not limited to, any carboxylic acid-based resins. Exemplary cation exchange resins include carboxymethyl (CM) resins, phosphate resins (based on phosphate functional groups), methanesulfonate (S) resins, and sulfopropyl (SP) resins.
[0341] The effect of anion exchange chromatography is to separate AAV particles from proteins, cells and other components present in the lysate and / or column eluate of the clarification from affinity or cation exchange or size exclusion chromatography. Anion exchange chromatography can also be used to reduce and thus control the amount of empty capsids in the eluate. For example, the anion exchange column with the rAAV particles combined therewith can be washed with a solution of NaCl comprising a moderate concentration (for example, about 100mM to 125mM, such as 110mM to 115mM), and a portion of empty capsids can be eluted when flowing through without eluting rAAV particles in large quantities. Subsequently, the rAAV particles bonded to the anion exchange column can be eluted using a solution comprising a higher concentration of NaCl (for example, about 130mM to 300mM NaCl), thereby producing the column eluate of the rAAV particles comprising rAAV vectors with empty capsids reduced or depleted and proportionally increased amounts.
[0342] Exemplary anion exchange resins include, but are not limited to, those based on polyamine resins and other resins.Examples of strong anion exchange resins include those generally based on quaternized nitrogen atoms, including but not limited to quaternary ammonium salt resins such as trialkylbenzylammonium resins. Suitable exchange chromatography materials include, but are not limited to, MACRO PREP Q (strong anion exchanger available from BioRad, Hercules, CA, USA); UNOSPHERE Q (strong anion exchanger available from BioRad, Hercules, CA, USA); POROS 50HQ (strong anion exchanger available from Applied Biosystems, Foster City, CA, USA); POROS XQ (strong anion exchanger available from Applied Biosystems, Foster City, CA, USA); POROS SOD (weak anion exchanger available from Applied Biosystems, Foster City, CA, USA); POROS 50PI (weak anion exchanger available from Applied Biosystems, Foster City, CA, USA); Capto Q, Capto XQ, Capto Q ImpRes, and SOURCE 30Q (strong anion exchangers available from GE Healthcare). Healthcare, Marlborough, MA, USA); DEAE SEPHAROSE (a weak anion exchanger available from Amersham Biosciences, Piscataway, NJ, USA); Q SEPHAROSE (a strong anion exchanger available from Amersham Biosciences, Piscataway, NJ, USA). Additional exemplary anion exchange resins include aminoethyl (AE), diethylaminoethyl (DEAE), diethylaminopropyl (DEPE), and quaternary aminoethyl (QAE).
[0343] Manufacturing processes for purifying recombinant AAV particles intended as products for treating human disease should achieve the following goals: 1) consistent particle purity, potency, and safety; 2) manufacturing process scalability; and 3) acceptable manufacturing costs.
[0344] An exemplary process for purification of recombinant AAV particles is reported in WO 2019 / 006390.
[0345] The recombinant adeno-associated virus particle (rAAV particle) purification and production methods outlined below are scalable to large scale. For example, to a suspension culture volume of 5, 10, 10-20, 20-50, 50-100, 100-200 or more liters. The recombinant adeno-associated virus particle purification and production methods are applicable to a variety of AAV serotypes / capsid variants.
[0346] In certain embodiments of all aspects and embodiments, purification of rAAV particles comprises the following steps:
[0347] (a) harvesting cells and / or cell culture supernatant containing rAAV particles to produce a harvest;
[0348] (b) optionally concentrating the harvest produced in step (a) to produce a concentrated harvest;
[0349] (c) lysing the harvest produced in step (a) or the concentrated harvest produced in step (b) to produce a lysate;
[0350] (d) treating the lysate produced in step (c) to reduce contaminating nucleic acids in the lysate, thereby producing a nucleic acid-reduced lysate;
[0351] (e) optionally filtering the nucleic acid-reduced lysate produced in step (d) to produce a clarified lysate, and optionally diluting the clarified lysate to produce a diluted clarified lysate;
[0352] (f) subjecting the nucleic acid-reduced lysate of step (d), the clarified lysate of step (e), or the diluted clarified lysate produced in step (e) to cation exchange column chromatography to produce a column eluate comprising rAAV particles, thereby separating the rAAV particles from protein impurities or other production / process related impurities, and optionally diluting the column eluate to produce a diluted column eluate;
[0353] (g) subjecting the column eluate produced in step (f) or the diluted column eluate to anion exchange chromatography to produce a second column eluate comprising rAAV particles, thereby separating the rAAV particles from protein impurities or production / process related impurities, and optionally concentrating the second column eluate to produce a concentrated second column eluate;
[0354] (h) subjecting the second column eluate or the concentrated second column eluate produced in step (g) to size exclusion column chromatography (SEC) to produce a third column eluate comprising rAAV particles, thereby separating the rAAV particles from protein impurities or production / process-related impurities, and optionally concentrating the third column eluate to produce a concentrated third column eluate; and
[0355] (i) filtering the third column eluate or the concentrated third column eluate produced in step (h) to produce purified rAAV particles;
[0356] The viral genome copy number is determined using the method according to the present invention in one or more of steps (a) to (i) or after that.
[0357] In certain embodiments, steps (a) to (f) are retained and combined with the following steps:
[0358] (g) subjecting the column eluate or the concentrated column eluate produced in step (f) to size exclusion column chromatography (SEC) to produce a second column eluate comprising rAAV particles, thereby separating the rAAV particles from protein impurities or other production / process related impurities, and optionally diluting the second column eluate to produce a concentrated second column eluate;
[0359] (h) subjecting the second column eluate or the diluted second column eluate produced in step (g) to anion exchange chromatography to produce a third column eluate comprising rAAV particles, thereby separating the rAAV particles from protein impurity production / process related impurities, and optionally diluting the third column eluate to produce a diluted third column eluate; and
[0360] (i) filtering the third column eluate or the concentrated third column eluate produced in step (h) to produce purified rAAV particles;
[0361] The viral genome copy number is determined using the method according to the present invention in one or more of steps (a) to (i) or after that.
[0362] In certain embodiments, steps (a) to (g) are retained and combined with the following steps:
[0363] (h) filtering the second column eluate or the concentrated second column eluate produced in step (g) to produce purified rAAV particles;
[0364] The viral genome copy number is determined using the method according to the present invention in one or more of steps (a) to (h) or thereafter.
[0365] In an embodiment, steps (a) to (e) are retained and combined with the following steps:
[0366] (f) subjecting the nucleic acid-reduced lysate of step (d) or the clarified lysate or the diluted clarified lysate produced in step (e) to AAV affinity column chromatography to produce a column eluate comprising rAAV particles, thereby separating the rAAV particles from protein impurities or other production / process-related impurities, and optionally concentrating the column eluate to produce a concentrated column eluate;
[0367] (g) subjecting the column eluate or the concentrated column eluate produced in step (f) to size exclusion column chromatography (SEC) to produce a second column eluate comprising rAAV particles, thereby separating the rAAV particles from protein impurities or other production / process related impurities, and optionally diluting the second column eluate to produce a diluted second column eluate;
[0368] (h) optionally subjecting the second column eluate or the diluted second column eluate produced in step (g) to anion exchange chromatography to produce a third column eluate comprising rAAV particles, thereby separating the rAAV particles from protein impurities or other production / process related impurities, and optionally diluting the third column eluate to produce a diluted third column eluate; and
[0369] (i) filtering the second column eluate or the diluted second column eluate produced in step (g), or filtering the third column eluate or the concentrated third column eluate produced in step (h), thereby producing purified rAAV particles;
[0370] The viral genome copy number is determined using the method according to the present invention in one or more of steps (a) to (i) or after that.
[0371] In certain embodiments of all aspects and embodiments, the concentration of step (b) and / or step (f) and / or step (g) and / or step (h) is performed via ultrafiltration / diafiltration, such as by tangential flow filtration (TFF).
[0372] In certain embodiments of all aspects and embodiments, the concentration of step (b) reduces the volume of harvested cells and cell culture supernatant by about 2 to 20 fold.
[0373] In certain embodiments of all aspects and embodiments, the concentrating of step (f) and / or step (g) and / or step (h) reduces the volume of the column eluate by about 5 to 20 fold.
[0374] In certain embodiments of all aspects and embodiments, the lysis of the harvest produced in step (a) or the concentrated harvest produced in step (b) is carried out by physical or chemical means. Non-limiting examples of physical means include microfluidization and homogenization. Non-limiting examples of chemical means include detergents. Detergents include nonionic and ionic detergents. Non-limiting examples of non-ionic detergents include Triton X-100. Non-limiting examples of detergent concentrations are between about 0.1% (v / v) or (w / v) and 1.0% (v / v) or (w / v), including end values.
[0375] In certain embodiments of all aspects and embodiments, step (d) comprises treating with a nuclease to reduce contaminating nucleic acids. Non-limiting examples of nucleases include benzonase.
[0376] In certain embodiments of all aspects and embodiments, the filtration of the clarified lysate or diluted clarified lysate of step (e) is performed via a filter. Non-limiting examples of filters are those having a pore size between about 0.1 microns and 10.0 microns (including end values).
[0377] In certain embodiments of all aspects and embodiments, the dilution of the clarified lysate of step (e) is performed with an aqueous buffered phosphate, acetate or Tris solution. Non-limiting examples of solution pH are between about pH 4.0 and pH 7.4, including end values. Non-limiting examples of Tris solution pH are greater than pH 7.5, such as between about pH 8.0 and pH 9.0, including end values.
[0378] In certain embodiments of all aspects and embodiments, the dilution of the column eluate of step (f) or the second column eluate of step (g) is carried out with an aqueous buffered phosphate, acetate or Tris solution. Non-limiting examples of solution pH are between about pH 4.0 and pH 7.4, including end values. Non-limiting examples of Tris solution pH are greater than pH 7.5, such as between about pH 8.0 and pH 9.0, including end values.
[0379] In certain embodiments of all aspects and embodiments, the rAAV particles produced in step (i) are formulated with a surfactant to produce a rAAV particle formulation.
[0380] In certain embodiments of all aspects and embodiments, the anion exchange column chromatography of steps (f), (g) and / or (h) comprises polyethylene glycol (PEG)-modulated column chromatography.
[0381] In certain embodiments of all aspects and embodiments, the anion exchange column chromatography of steps (g) and / or (h) is washed with a PEG solution prior to eluting the rAAV particles from the column.
[0382] In certain embodiments of all aspects and embodiments, the average molecular weight of PEG is in the range of about 1,000 g / mol to 80,000 g / mol, inclusive.
[0383] In certain embodiments of all aspects and embodiments, the concentration of PEG is about 4% (w / v) to about 10% (w / v), inclusive.
[0384] In certain embodiments of all aspects and embodiments, the anion exchange column of steps (g) and / or (h) is washed with an aqueous surfactant solution prior to eluting the rAAV particles from the column.
[0385] In certain embodiments of all aspects and embodiments, the cation exchange column of step (f) is washed with a surfactant solution prior to eluting the rAAV particles from the column.
[0386] In certain embodiments of all aspects and embodiments, the PEG solution and / or the surfactant solution comprises an aqueous Tris-HCl / NaCl buffer, an aqueous phosphate / NaCl buffer, or an aqueous acetate / NaCl buffer.
[0387] In certain embodiments of all aspects and embodiments, the NaCl concentration in the buffer or solution ranges between about 20 mM to 300 mM NaCl, inclusive, or between about 50 mM to 250 mM NaCl, inclusive.
[0388] In certain embodiments of all aspects and embodiments, the surfactant comprises a cationic or anionic surfactant.
[0389] In certain embodiments of all aspects and embodiments, the surfactant comprises a twelve carbon chain surfactant.
[0390] In certain embodiments of all aspects and embodiments, the surfactant comprises dodecyltrimethylammonium chloride (DTAC) or Sarkosyl.
[0391] In certain embodiments of all aspects and embodiments, the rAAV particles are eluted from the anion exchange column of steps (f), (g) and / or (h) with aqueous Tris-HCl / NaCl buffer.
[0392] In certain embodiments of all aspects and embodiments, the Tris-HCl / NaCl buffer comprises 100 mM to 400 mM NaCl (inclusive), optionally at a pH in the range of about pH 7.5 to about pH 9.0 (inclusive).
[0393] In certain embodiments of all aspects and embodiments, the anion exchange column of steps (f), (g) and / or (h) is washed with aqueous Tris-HCl / NaCl buffer.
[0394] In certain embodiments of all aspects and embodiments, the NaCl concentration in the aqueous Tris-HCl / NaCl buffer is in the range of about 75 mM to 125 mM, inclusive.
[0395] In certain embodiments of all aspects and embodiments, the aqueous Tris-HCl / NaCl buffer has a pH of about pH 7.5 to about pH 9.0, inclusive.
[0396] In certain embodiments of all aspects and embodiments, the anion exchange column of steps (f), (g) and / or (h) is washed one or more times to reduce the amount of empty capsids in the second or third column eluate.
[0397] In certain embodiments of all aspects and embodiments, washing of the anion exchange column removes empty capsids from the column prior to and / or in place of elution of the rAAV particles, thereby reducing the amount of empty capsids in the second or third column eluate.
[0398] In certain embodiments of all aspects and embodiments, washing the anion exchange column removes at least about 50% of the total empty capsids from the column prior to and / or in place of elution of the rAAV particles, thereby reducing the amount of empty capsids in the second or third column eluate by about 50%.
[0399] In certain embodiments of all aspects and embodiments, the NaCl concentration in the aqueous Tris-HCl / NaCl buffer is in the range of about 110 mM to 120 mM, inclusive.
[0400] In certain embodiments of all aspects and embodiments, the ratio and / or amount of eluted rAAV particles and empty capsids is controlled by a wash buffer.
[0401] In certain embodiments of all aspects and embodiments, the rAAV particles are eluted from the cation exchange column of step (f) in an aqueous phosphate / NaCl buffer or an aqueous acetate / NaCl buffer. Non-limiting NaCl concentrations in the buffer range from about 125 mM to 500 mM NaCl, inclusive. Non-limiting examples of buffer pH range from about pH 5.5 to about pH 7.5, inclusive.
[0402] In certain embodiments of all aspects and embodiments, the anion exchange column of steps (f), (g) and / or (h) comprises quaternary ammonium functional groups, such as quaternized polyethyleneimine.
[0403] In certain embodiments of all aspects and embodiments, the size exclusion column (SEC) of step (g) and / or (h) has a separation / fractionation range (molecular weight) of about 10,000 g / mol to about 600,000 g / mol (inclusive).
[0404] In certain embodiments of all aspects and embodiments, the cation exchange column of step (f) comprises a sulfonic acid or a functional group, such as a sulfopropyl group.
[0405] In certain embodiments of all aspects and embodiments, the AAV affinity column comprises a protein or ligand that binds to an AAV capsid protein. Non-limiting examples of proteins include antibodies that bind to an AAV capsid protein. More specific non-limiting examples include single-chain llama antibodies (Camelidae) that bind to an AAV capsid protein.
[0406] In certain embodiments of all aspects and embodiments, the method does not comprise the step of cesium chloride gradient ultracentrifugation.
[0407] In certain embodiments of all aspects and embodiments, the method recovers about 50% to 90% of the total rAAV particles from the harvest produced in step (a) or the concentrated harvest produced in step (b).
[0408] In certain embodiments of all aspects and embodiments, the method produces rAAV particles having a higher purity than rAAV particles produced or purified by a single AAV affinity column purification.
[0409] In certain embodiments of all aspects and embodiments, steps (c) and (d) are performed substantially simultaneously.
[0410] In certain embodiments of all aspects and embodiments, after step (c) but before step (f), the NaCl concentration is adjusted to within the range of about 100 mM to 400 mM NaCl (inclusive), or within the range of about 140 mM to 300 mM NaCl (inclusive).
[0411] In certain embodiments of all aspects and embodiments, the cells are cells growing in suspension or adherently.
[0412] In certain embodiments of all aspects or embodiments, the cell is a mammalian cell. Non-limiting examples include HEK cells, such as HEK-293 cells, and CHO cells, such as CHO-K1 cells.
[0413] Methods for determining the infectious titer of rAAV particles containing a transgene are known in the art (see, e.g., Zhen et al., Hum. Gene Ther. 15 (2004) 709). Methods for determining empty capsids and rAAV particles with packaged transgenes are known (see, e.g., Grimm et al., Gene Therapy 6 (1999) 1322-1330; Sommer et al., Malec. Ther. 7 (2003) 122-128).
[0414] In order to determine the presence or amount of degraded / denatured capsids, purified rAAV particles can be subjected to SDS-polyacrylamide gel electrophoresis, which consists of any gel (e.g., gradient gel) capable of separating the three capsid proteins, and then running the gel until the sample is separated and blotted onto a nylon or nitrocellulose membrane. Anti-AAV capsid antibodies are then used as primary antibodies that bind to denatured capsid proteins (see, e.g., Wobus et al., J. Viral. 74 (2000) 9281-9293). The secondary antibody that binds the primary antibody contains a tool for detecting the primary antibody. Semi-quantitative detection of the binding between the primary and secondary antibodies determines the amount of capsids. Another method is to use an analytical HPLC or analytical ultracentrifuge using a SEC column.
[0415] ***
[0416] In addition to the various embodiments depicted and claimed, the disclosed subject matter also relates to other embodiments having other combinations of features disclosed and claimed herein. Thus, the specific features presented herein may be combined with each other in other ways within the scope of the disclosed subject matter, such that the disclosed subject matter includes any suitable combination of features disclosed herein. For purposes of illustration and description, the foregoing description of specific embodiments of the disclosed subject matter has been presented. It is not intended to be exhaustive or to limit the disclosed subject matter to those embodiments disclosed.
[0417] All references mentioned herein are hereby incorporated by reference.
[0418] ***
[0419] The following examples are provided to aid the understanding of the present invention, the true scope of the invention being set forth in the appended claims.It should be understood that modifications may be made to the procedures set forth without departing from the spirit of the present invention.
[0420] Examples
[0421] General techniques
[0422] 1) Recombinant DNA technology
[0423] Standard methods were used to manipulate DNA, such as described in Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989). Molecular biology reagents were used according to the manufacturers' instructions.
[0424] 2) DNA and protein sequence analysis and sequence data management
[0425] The EMBOSS (European Molecular Biology Open Software Suite) software package and Invitrogen's Vector NTI and Geneious Prime were used for sequence creation, mapping, analysis, annotation, and illustration.
[0426] 3) Gene and oligonucleotide synthesis
[0427] The desired gene segments were prepared by chemical synthesis at Geneart GmbH (Regensburg, Germany). The synthesized gene fragments were cloned into E. coli plasmids for propagation / amplification. The DNA sequences of the subcloned gene fragments were verified by DNA sequencing. Alternatively, short synthetic DNA fragments were assembled by annealing chemically synthesized oligonucleotides or via PCR. Individual oligonucleotides were prepared by metabion GmbH (Planegg-Martinsried, Germany).
[0428] 4) Reagents
[0429] If not stated otherwise, all commercial chemicals, antibodies and kits were used as provided according to the manufacturers' protocols.
[0430] 5) Cloning
[0431] conventional
[0432] For plasmid, use the cloning strategy via restriction enzyme.By selecting suitable restriction enzyme, desired target gene can be excised, and then inserted into different plasmids by connection.Therefore, preferably use and select the enzyme that cuts in the multiple cloning site (MCS) in a clever way, so that the connection of fragment can be carried out in the correct array.If plasmid and fragment are cut with the same restriction enzyme before, then the sticky end of fragment and plasmid fits perfectly together, and can be connected by DNA ligase subsequently.After connection, transform competent E. coli cells with the newly generated plasmid.
[0433] Cloning by restriction digestion
[0434] For digestion of plasmid with restriction enzymes, pipette the following components together on ice:
[0435] Table 11: Restriction digestion reaction mixture
[0436]
[0437] If more enzymes were used in one digestion, 1 μL of each was used and the volume was adjusted by adding more or less PCR-grade water. All enzymes were chosen on the premise that they were qualified for use with CutSmart buffer from New England Biolabs (100% activity) and had the same incubation temperature (37°C for all).
[0438] The incubation was performed using a thermomixer or thermocycler, allowing the samples to incubate at a constant temperature (37°C). During the incubation, the samples were not agitated. The incubation time was set to 60 minutes. The samples were then mixed directly with the loading dye and loaded onto an agarose electrophoresis gel or stored at 4°C / ice for further use.
[0439] Prepare 1% agarose gel for gel electrophoresis. Therefore, 1.5g of multi-purpose agarose is weighed into a 125 conical shake flask and filled with 150mL TAE buffer. The mixture is heated in a microwave oven until the agarose is completely dissolved. 0.5μg / mL of ethidium bromide is added to the agarose solution. The gel is then cast in a mold. After the agarose is shaped, the mold is placed in the electrophoresis chamber and the chamber is filled with TAE buffer. The sample is then loaded. In the first pocket (starting from the left), the appropriate DNA molecular weight marker is loaded, followed by the sample. The gel is run at <130V for about 60 minutes. After electrophoresis, the gel is removed from the chamber and analyzed in a UV-Imager.
[0440] The band was cut and transferred into a 1.5 mL Eppendorf tube. For purification of the gel, the QIAquick Gel Extraction Kit from Qiagen was used according to the manufacturer's instructions. The DNA fragments were stored at -20 °C for further use.
[0441] The fragments for ligation are pipetted together at a plasmid / insert molar ratio of 1:2, 1:3 or 1:5, depending on the length of the insert and plasmid fragments and their relationship to each other. If the fragment that should be inserted into the plasmid is short, a ratio of 1:5 is used. If the insert is long, a smaller amount of plasmid is used. A plasmid amount of 50ng is used in each ligation, and the specific amount of the insert is calculated using the NEBioCalculator. For ligation, a T4 DNA ligation kit from NEB is used. Table 12 below depicts an example of a ligation mixture.
[0442] Table 12: Ligation Reaction Mixture
[0443]
[0444] Start by mixing the DNA and water, add the buffer and finally the enzyme, pipetting all components together onto ice. Gently mix the reaction by pipetting up and down, briefly microcentrifuge, and then incubate at room temperature for 10 minutes. After incubation, heat inactivate the T4 ligase at 65°C for 10 minutes. Cool the sample on ice. In the last step, transform 10-beta competent E. coli cells (see below) with 2 μL of the ligated plasmid.
[0445] Transformation of 10-β competent E. coli cells
[0446] For transformation, 10-β competent E. coli cells were thawed on ice. Afterwards, 2 μL of plasmid DNA was directly transferred to the cell suspension. The test tube was flicked and placed on ice for 30 minutes. Thereafter, the cells were placed in a 42°C heat block and heat-shocked for exactly 30 seconds. Immediately thereafter, the cells were cooled on ice for 2 minutes. 950 μL of NEB 10-β growth medium was added to the cell suspension. The cells were incubated at 37°C with shaking for one hour. Then, 50 μL to 100 μL were transferred to a preheated (37°C) LB-Amp agar plate and plated with a disposable spatula. The plates were incubated overnight at 37°C. Only bacteria that successfully incorporated a plasmid carrying a resistance gene for ampicillin could grow on these plates. Single colonies were picked the next day and cultured in LB-Amp medium for subsequent plasmid preparation.
[0447] Bacterial culture
[0448] The culture of E. coli was carried out in LB medium (abbreviation of Luria Bertani) into which 1 mL / L of 100 mg / mL ampicillin was added so that the ampicillin concentration was 0.1 mg / mL. For different plasmid preparation quantities, the following amounts were inoculated with a single bacterial colony.
[0449] Table 13: E. coli culture volume
[0450] Quantitative plasmid preparation Volume LB-Amp medium [mL] Incubation time [h] Miniprep 96-well (EpMotion) 1.5 23 Small preparation 15mL-tube 3.6 23 Large-scale preparation 200 16
[0451] For small-scale preparation, fill each well of a 96-well 2 mL deep-well plate with 1.5 mL of LB-Amp medium. Pick a colony and insert a toothpick into the medium. When all colonies are picked, seal the plate with a sticky air porous membrane. Incubate the plate in a 37°C incubator at a shaking speed of 200 rpm for 23 hours.
[0452] For small-scale preparation, 3.6 mL of LB-Amp medium was filled in a 15 mL tube (with vented cap) and inoculated with bacterial colonies. During incubation, the toothpick was not removed but left in the tube. As with the 96-well plate, the tube was incubated at 37°C, 200 rpm for 23 hours.
[0453] For large-scale preparation, 200 mL of LB-Amp medium was filled into an autoclaved 1 L Erlenmeyer glass flask and inoculated with 1 mL of bacterial day culture approximately 5 hours later. The Erlenmeyer flask was closed with a paper stopper and incubated at 37°C, 200 rpm for 16 hours.
[0454] Plasmid preparation
[0455] For miniprep, 50 μL of bacterial suspension was transferred to a 1 mL deep well plate. Afterwards, the bacterial cells were centrifuged in the plate at 3000 rpm, 4°C for 5 min. The supernatant was removed and the plate with the bacterial pellet was placed in the EpMotion. After approximately 90 minutes, the run was completed and the eluted plasmid DNA could be removed from the EpMotion for further use.
[0456] For the miniprep, remove the 15 mL tube from the incubator and aliquot 3.6 mL of the bacterial culture into two 2 mL Eppendorf tubes. Centrifuge the tubes at 6,800 x g for 3 minutes at room temperature in a benchtop microcentrifuge. Afterwards, perform the miniprep using the Qiagen QIAprep Spin Miniprep Kit according to the manufacturer's instructions. Measure the concentration of the plasmid DNA using a Nanodrop.
[0457] Large quantities were prepared using the Macherey-Nagel method according to the manufacturer's instructions. Xtra MaxiEF kit was used. DNA concentration was measured with Nanodrop.
[0458] Ethanol precipitation
[0459] Mix a volume of DNA solution with 2.5 volumes of 100% ethanol. Incubate the mixture at -20°C for 10 minutes. Then centrifuge the DNA at 14,000rpm, 4°C for 30 minutes. Carefully remove the supernatant and wash the pellet with 70% ethanol. Centrifuge the tube again at 14,000rpm, 4°C for 5 minutes. Carefully remove the supernatant by pipetting and dry the pellet. When the ethanol evaporates, add an appropriate amount of endotoxin-free water. Give the DNA time to redissolve in 4°C water overnight. Take a small portion and measure the DNA concentration using a Nanodrop device.
[0460] Expression cassette composition
[0461] For expression of open reading frames, transcription units are used that contain at least the following functional elements:
[0462] - promoter,
[0463] - a nucleic acid comprising a corresponding open reading frame, if desired, including a signal sequence,
[0464] - polyadenylation signal sequence.
[0465] In addition to the expression unit / cassette containing the desired gene to be expressed, the basic / standard mammalian expression plasmid also contains
[0466] - an origin of replication from the plasmid pUC18, which allows replication of this plasmid in E. coli, and
[0467] -β-lactamase gene, which confers ampicillin resistance in Escherichia coli.
[0468] 6) Cell culture technology
[0469] Standard cell culture techniques were used as described in Current Protocols in Cell Biology (2000), Bonifacino, JS, Dasso, M., Harford, JB, Lippincott-Schwartz, J. and Yamada, KM (Eds.), John Wiley & Sons, Inc.
[0470] Transient transfection in HEK293 system
[0471] Cells producing recombinant AAV particles have been generated by transient transfection with the corresponding plasmids using the HEK293 system (Invitrogen, now Thermo Scientific) according to the manufacturer's instructions. Briefly, cells were grown in shake flasks or stirred fermentation tubes in serum-free FreeStyle TM HEK293 cells (Invitrogen) grown in suspension in 293 expression medium (Invitrogen) were incubated with the corresponding plasmids and 293fectin TM For 2L shake flasks (Corning), HEK293 cells were transfected at 1*10 6 The cells were inoculated at a density of 10 cells / mL in 600 mL and incubated at 120 rpm and 8% CO2. The next day, the cells were cultured at a density of about 1.5*10 6 Cells / mL were transfected with a cell density of about 42 mL of a mixture of the following: A) 20 mL Opti-MEM (Invitrogen) with 600 μg total plasmid DNA (1 μg / mL) and B) 20 mL Opti-MEM + 1.2 mL 293fectin or fectin (2 μL / mL). Glucose solution was added during the fermentation process according to glucose consumption.
[0472] Example 1
[0473] No pre-processing
[0474] program:
[0475] - Mix 90μL H2O and 10μL sample
[0476] - Incubate at 95°C for 15 minutes
[0477] Examples:
[0478] 1. Process samples
[0479] 2. Preparation of PCR Master Mix
[0480] 3. Add the master mix to the plate
[0481] 4. Prepare a 1:10 dilution with water
[0482] 5. Add templates to the board
[0483] 6. Seal the plate and vortex (1 minute, 2.200 rpm) and centrifuge
[0484] 7. Form droplets (20 μL final mixture + 70 μL oil) using an automated droplet generator (Auto-DG) and transfer to a plate (42 μL)
[0485] 8. Seal the plate and start the PCR run
[0486] Example 2
[0487] Heat denaturation
[0488] program:
[0489] - Incubate the samples at 98°C for 10 minutes
[0490] Examples:
[0491] 1. Heat denaturation
[0492] 2. Preparation of PCR Master Mix
[0493] 3. Add the master mix to the plate
[0494] 4. Prepare a 1:10 dilution with water
[0495] 5. Add templates to the board
[0496] 6. Seal the plate and vortex (1 minute, 2.200 rpm) and centrifuge
[0497] 7. Form droplets using Auto-DG (20 μL final mixture + 70 μL oil) and transfer to plate (42 μL)
[0498] 8. Seal the plate and start the PCR run
[0499] Example 3
[0500] DNase I digestion
[0501] Reagents:
[0502] 1) DNase I buffer (Promega): 400 mM Tris-HCl, pH 8, 100 mM MgSO4, 10 mM CaCl2
[0503] 2) DNase I (Promega): 50 U / mL diluted to 1 U / μL
[0504] Procedure (50 μL reaction volume):
[0505] -Mix 30μL H2O, 5μL DNase I buffer, 5μL DNase I, 10μL sample
[0506] - Incubate at 37°C for 30 minutes.
[0507] - Heat to 95°C for 15 minutes.
[0508] Procedure (100 μL reaction volume):
[0509] -Mix 75μL H2O, 10μL DNase I buffer, 5μL DNase I, 10μL sample
[0510] - Incubate at 37°C for 30 minutes.
[0511] - Heat to 95°C for 15 minutes.
[0512] Examples:
[0513] 1. DNase I digestion;
[0514] 2. Add 50 μL of water to the reaction mixture
[0515] 3. Preparation of PCR Master Mix
[0516] 4. Add PCR master mix to the plate (16.5 μL per well)
[0517] 5. Prepare 1:10 dilution: 10 μL sample / plasmid / standard + 90 μL H2O
[0518] 6. Add template to plate (5.5 μL per well)
[0519] 7. Seal the plate and vortex (1 minute, 2.200 rpm) and centrifuge (1 minute, 1000 rcf)
[0520] 8. Form droplets using Auto-DG (20 μL final mixture + 70 μL oil) and transfer to plate (42 μL)
[0521] 9. Seal the plate and start the PCR run
[0522] Example 4
[0523] Proteinase K digestion
[0524] Reagents:
[0525] 1) Proteinase K (Roche; 17.8 mg / mL = ≥ 50 U / mL): diluted to 1 U / mL
[0526] 2) Proteinase K buffer (BioRad): 400 mM Tris-HCl, 20 mM EDTA, 2000 mM NaCl, pH 8
[0527] 3) Sodium dodecyl sulfate solution (SDS solution): 10%
[0528] Procedure (Water):
[0529] - Mix 68 μL of water with 10 μL of sample and add 20 μL of proteinase K
[0530] - Incubate at 50°C for 60 minutes
[0531] -Heat to 95°C for 15 minutes
[0532] Procedure (buffer without SDS):
[0533] - Mix 63 μL of water with 5 μL of proteinase K buffer and add 10 μL of sample and 20 μL of proteinase K
[0534] - Incubate at 50°C for 60 minutes
[0535] -Heat to 95°C for 15 minutes
[0536] Procedure (buffer containing SDS):
[0537] - Mix 53 μL of water with 5 μL of proteinase K buffer and add 10 μL of SDS solution, 10 μL of sample and 20 μL of proteinase K
[0538] - Incubate at 50°C for 60 minutes
[0539] -Heat to 95°C for 15 minutes
[0540] Examples:
[0541] 1. Proteinase K Digestion
[0542] 2. Preparation of PCR Master Mix
[0543] 3. Add the master mix to the plate (16.5 μL per well)
[0544] 4. Prepare 1:10 dilution: 10 μL sample + 90 μL H2O
[0545] 5. Add template to plate (5.5 μL per well)
[0546] 6. Seal the plate and vortex (1 minute, 2.200 rpm) and centrifuge (1 minute, 1000 rcf)
[0547] 7. Form droplets using Auto-DG (20 μL final mixture + 70 μL oil) and transfer to plate (42 μL)
[0548] 8. Seal the plate and start the PCR run
[0549] Example 5
[0550] Heat denaturation followed by proteinase K digestion
[0551] Reagents:
[0552] 1) Proteinase K (Roche; 17.8 mg / mL = ≥ 50 U / mL): 1 U / mL
[0553] 2) Proteinase K buffer (BioRad): 400 mM Tris-HCl, 20 mM EDTA, 2000 mM NaCl, pH 8
[0554] program:
[0555] - Heat denaturation: Incubate the sample at 98°C for 10 minutes
[0556] - Proteinase K digestion: 1 μL proteinase K per 50 μL sample; incubate at 50°C for 30 minutes; inactivate at 95°C for 10 minutes.
[0557] Examples:
[0558] 1. Heat denaturation
[0559] 2. Proteinase K Digestion
[0560] 3. Prepare 1:10 dilution: 10 μL sample + 90 μL H2O
[0561] 4. Preparation of PCR Master Mix
[0562] 5. Add the master mix to the plate
[0563] 6. Add samples to the plate
[0564] 7. Seal the plate and vortex (1 minute, 2.200 rpm) and centrifuge
[0565] 8. Form droplets using Auto-DG (20 μL final mixture + 70 μL oil) and transfer to plate (42 μL)
[0566] 9. Seal the plate and start the PCR run
[0567] Example 6
[0568] DNase I digestion followed by proteinase K digestion
[0569] Method 1:
[0570] Reagents:
[0571] 1) DNase I buffer (Promega): 400 mM Tris-HCl, pH 8, 100 mM MgSO4, 10 mM CaCl2
[0572] 2) DNase I (Promega): 1 U / μL
[0573] 3) Proteinase K (Roche; 17.8 mg / mL = ≥ 50 U / mL): 1 U / mL
[0574] 4) Proteinase K buffer (BioRad): 400 mM Tris-HCl, 20 mM EDTA, 2000 mM NaCl, pH 8
[0575] 5) Sodium dodecyl sulfate solution (SDS solution): 10%
[0576] program:
[0577] -Mix 30μL H2O, 5μL DNase I buffer, 5μL DNase I, 10μL sample
[0578] - Incubate at 37°C for 30 minutes.
[0579] - Heat to 95°C for 15 minutes.
[0580] - Mix 50 μL PK-mix (42 μL H2O + 2 μL proteinase K + 5 μL 20x proteinase K buffer + 1 μL 10% SDS solution) with 50 μL of incubated DNase I-mix
[0581] - Incubate at 50°C for 60 minutes
[0582] - Heat to 95°C for 15 minutes.
[0583] Examples:
[0584] 1. DNase I digestion; optionally dilute 1:10
[0585] 2. Proteinase K digestion; dilution 1:10
[0586] 3. Preparation of PCR Master Mix
[0587] 4. Add PCR master mix to the plate (16.5 μL per well)
[0588] 5. Prepare 1:10 dilution: 10 μL sample + 90 μL H2O
[0589] 6. Add template to plate (5.5 μL per well)
[0590] 7. Seal the plate and vortex (1 minute, 2.200 rpm) and centrifuge (1 minute, 1000 rcf)
[0591] 8. Form droplets using Auto-DG (20 μL final mixture + 70 μL oil) and transfer to plate (42 μL)
[0592] 9. Seal the plate and start the PCR run
[0593] Method 2:
[0594] Reagents:
[0595] 1) Proteinase K (NEB; about 20 mg / mL = ≥ 800 U / mL): dilute to 16 U / mL
[0596] 2) Proteinase K buffer (BioRad): 400 mM Tris-HCl, 20 mM EDTA, 2000 mM NaCl
[0597] 3) Sodium dodecyl sulfate solution (SDS solution): 10%
[0598] Procedure (buffer containing SDS):
[0599] - Mix 42 μL of water with 50 μL of sample (DNase I digestion solution) and add 2 μL of proteinase K, 5 μL of proteinase K buffer and 1 μL of SDS solution
[0600] - Incubate at 50°C for 60 minutes
[0601] -Heat to 95°C for 15 minutes
[0602] Examples:
[0603] 1. DNase I Digestion
[0604] 2. Proteinase K Digestion
[0605] 3. Dilution 1:10
[0606] 4. Preparation of PCR Master Mix
[0607] 5. Add the master mix to the plate (16.5 μL per well)
[0608] 6. Prepare 1:10 dilution: 10 μL sample + 90 μL H2O
[0609] 7. Add template to plate (5.5 μL per well)
[0610] 8. Seal the plate and vortex (1 minute, 2.200 rpm) and centrifuge (1 minute, 1000 rcf)
[0611] 9. Form droplets using Auto-DG (20 μL final mixture + 70 μL oil) and transfer to plate (42 μL)
[0612] 10. Seal the plate and start the PCR run Example 7
[0613] Condition comparison
[0614] Reagents and procedures were as outlined in previous examples.
[0615] The conditions are according to Tables 14 and 15 below.
[0616] Table 14:
[0617]
[0618] Table 15:
[0619]
[0620]
[0621] Example 8
[0622] ddPCR
[0623] For viral genome titration, a duplex ddPCR assay was performed. Primers and probes were designed for ITR sites and Amp resistance sequences present on the backbone of all three plasmids used in rAAV production. PCR master mix was prepared according to Table 16 (Droplet Digital PCR Guide - Bio-Rad).
[0624] Table 16: ddPCR master mix composition.
[0625] Components Volume per well [μL] Final concentration Supermix (2x) 11 1x 20 μM ITR forward primer 0.99 900nM 20 μM ITR reverse primer 0.99 900nM 20 μM FAM-labeled ITR probe 0.275 250nM 20 μM Amp forward primer 0.99 900nM 20 μM Amp reverse primer 0.99 900nM 20 μM HEX-labeled Amp probe 0.275 250nM template 5.5 1*10E4-1*10E5 copies / mL water 0.99 - total 22
[0626] The prepared master mix was transferred into a 96-well plate, 16.5 μL per well. Then, the pre-treated sample was serially diluted: 10 μL of sample was transferred to 90 μL of water in a LoBind tube using LoRentention Tips and mixed thoroughly. Thereafter, 5.5 μL of sample was added to the master mix solution in the 96-well plate through several dilution steps. The plate was sealed at 180°C, vortexed at 2,200 rpm for 1 minute and centrifuged at 1,000 rpm for another minute. 20 μL of PCR mixture was taken out from each well using an automatic droplet generator device, producing up to 20,000 droplets per well, and transferred to another 96-well plate. After sealing the droplet plate at 180°C, a PCR run was performed. The corresponding conditions are shown in Table 17 below.
[0627] Table 17: ddPCR thermal cycling program.
[0628] Cycle times transsexual annealing Final extension Finish 1 95°C, 10 min 40 94°C, 30 seconds 60℃,1min 1 98℃,10min 12℃, maintain
[0629] In the droplet reader, the fluorescence signal for each droplet is measured in the FAM and HEX channels. QuantaSoft software processes the reader data and calculates the copy number for the target sequence, ITR site, and Amp in each 20 μL well. The initial sample titer can be determined by the following equation 1:
[0630]
[0631] Example 9
[0632] rAAV production
[0633] HEK293-F suspension cells were transfected with three plasmids, namely pAAV-transgene (EGFP or EBFP), pAAV-rep / cap and pAAV-helper. Plasmid DNA (1 μg / 1 mL cell culture) and lipid transfection reagent PEI pro (2 μL / 1 mL cell culture) were mixed with OptiMEM (50 μL / 1 mL cell culture) (see, e.g., Grieger, J. et al. 2016). The two solutions were then combined, incubated at room temperature for 15 minutes and added to a HEK293-F cell suspension (1*10E6 cells / mL) in F17 medium. The cells were incubated at 37°C, 8% CO2, 120 rpm for 48 to 72 hours (Grieger, J. et al. (2016)).
[0634] Recombinant AAV particles were harvested by adding lysis buffer (100 μL / 1 mL cell culture) containing 1% Triton X-100, 500 mM TRIS and 20 mM MgCl2 (pH 7.5). Freshly diluted Benzonase (10 μL / 1 mL cell culture) was added to a final concentration of 50 U / mL. After 60 minutes, lysis was performed under stirring at 37°C, MgSO4 (final concentration 37.5 mM) was added, and the cell lysis liquid medium was incubated for another 30 minutes (Chahal, P. et al. (2014)). The lysate suspension was then centrifuged at 4,000 g for 20 minutes and the supernatant was filtered through a 0.22 μm filter. The resulting product was considered a crude lysate.
[0635] Example 10
[0636] rAAV purification
[0637] The YMC glass columns are filled with POROS CaptureSelect AAVx affinity resin in a 9.1 mL bed volume. These resin beads are coated with antibody fragments that bind to multiple AAV serotypes with high specificity (POROS CaptureSelect AAV Resin – User Guide 2017).
[0638] First, the column was equilibrated with phosphate buffered saline (PBS) to produce the correct binding conditions. Then, the crude filtered lysate was loaded at 150 cm / h. After capturing the rAAV capsids, the column was washed with 4 column volumes (CV) of PBS and then 4 CV of 0.5 M NaCl to remove impurities such as cell debris and DNA residues. Another washing step with 4 CV of PBS was performed to prepare the elution conditions (POROS CaptureSelect AAV Resin – User Guide 2017).
[0639] The rAAV capsids were then eluted in 100 mM citrate buffer (pH 2.4) (POROS CaptureSelect AAV Resin – User Guide 2017). Fractions within the elution peak were pooled (UV detection at λ = 280 nm). The pH was raised to pH 7.5 using 2M TRIS (pH 9). Finally, the eluate was sterile filtered using a syringe filter with a pore size of 0.2 μm.
Claims
1. A method for determining the number of viral genomic DNA copies in a sample, wherein the method The following steps are involved: - incubating the sample with proteinase K, - determining the viral genomic DNA copy number by digital droplet polymerase chain reaction, wherein the sample does not contain DNA that is not encapsidated within a viral particle, wherein said incubation with proteinase K is performed in the presence of 0.05 (w / v) % to 1.5 (w / v) % sodium dodecyl sulfate.
2. The method according to claim 1, wherein the method The following steps are involved: - incubating the sample with a nuclease to obtain a digested sample, - incubating the digested sample with proteinase K to obtain a proteinase K-incubated sample, - Determining the viral genomic DNA copy number in the proteinase K-incubated sample by digital droplet polymerase chain reaction.
3. The method of claim 2, wherein the digested sample is diluted up to 2.5 times for the incubation with proteinase K.
4. The method according to any one of claims 2 to 3, wherein the entire digested sample is incubated with proteinase K.
5. The method according to any one of claims 1 to 4, wherein the method is performed at a temperature of up to 95°C, except for the final extension step of the digital droplet polymerase chain reaction.
6. The method according to any one of claims 1 to 5, wherein the total amount of proteinase K employed in the incubation is 15 mU to 35 mU.
7. The method according to any one of claims 1 to 6, wherein the volume of the sample is about 10 μL.
8. The method according to any one of claims 1 to 7, wherein the incubation with proteinase K is performed in a total volume of 100 μL.
9. The method according to any one of claims 2 to 8, wherein the nuclease is DNase I.
10. The method according to any one of claims 2 to 9, wherein the total amount of nuclease employed in the incubation is about 5 U.
11. The method according to any one of claims 2 to 10, wherein the incubation with the nuclease is performed in a total volume of 50 μL.
12. The method according to any one of claims 2 to 11, wherein the incubation with the nuclease is carried out in 40 mM Tris*HCl, 10 mM MgSO 4 , 1 mM CaCl 2 The final concentration is carried out at a pH of about 8.
13. The method according to any one of claims 2 to 12, wherein the incubation with the nuclease is at 37°C for 30 minutes, followed by inactivation of the nuclease at 95°C for 15 minutes.
14. The method according to any one of claims 1 to 13, wherein the incubation with proteinase K is performed at a final concentration of 20 mM Tris*HCl, 1 mM EDTA, 100 mM NaCl, 1 (w / v)% sodium dodecyl sulfate at a pH of about 8.
15. The method according to any one of claims 1 to 13, wherein the incubation with proteinase K is carried out in 30 mM Tris*HCl, 5 mM MgSO 4 , 0.5 mM CaCl 2 The reaction was carried out at a final concentration of about 8 with 0.5 mM EDTA, 50 mM NaCl, and 0.1 (w / v)% sodium dodecyl sulfate.
16. The method according to any one of claims 1 to 15, wherein the incubation with proteinase K is at 50°C for 60 minutes, followed by inactivation of the proteinase at 95°C for 15 minutes.
17. The method according to any one of claims 1 to 16, wherein all steps of the method are performed at a temperature of up to 95°C, except for the final extension step of the digital droplet polymerase chain reaction.
